EP3463342A1 - Associations de modulateurs du récepteur des oestrogènes - Google Patents
Associations de modulateurs du récepteur des oestrogènesInfo
- Publication number
- EP3463342A1 EP3463342A1 EP17803574.7A EP17803574A EP3463342A1 EP 3463342 A1 EP3463342 A1 EP 3463342A1 EP 17803574 A EP17803574 A EP 17803574A EP 3463342 A1 EP3463342 A1 EP 3463342A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituted
- unsubstituted
- nhc
- heterocycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002834 estrogen receptor modulator Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 91
- 201000011510 cancer Diseases 0.000 claims abstract description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 64
- 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 21
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 379
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 351
- 125000001072 heteroaryl group Chemical group 0.000 claims description 277
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 250
- 150000001875 compounds Chemical class 0.000 claims description 216
- 125000003118 aryl group Chemical group 0.000 claims description 206
- -1 -CONH2 Chemical group 0.000 claims description 173
- 125000000217 alkyl group Chemical group 0.000 claims description 152
- 229910052736 halogen Inorganic materials 0.000 claims description 110
- 150000002367 halogens Chemical class 0.000 claims description 108
- 229910005948 SO2Cl Inorganic materials 0.000 claims description 106
- 102000015694 estrogen receptors Human genes 0.000 claims description 101
- 108010038795 estrogen receptors Proteins 0.000 claims description 101
- 125000001424 substituent group Chemical group 0.000 claims description 99
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 98
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 77
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 72
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 69
- 229910006069 SO3H Inorganic materials 0.000 claims description 69
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 69
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 69
- 239000003112 inhibitor Substances 0.000 claims description 64
- 229910052757 nitrogen Inorganic materials 0.000 claims description 52
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 47
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 claims description 47
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 46
- 125000002947 alkylene group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 41
- 230000000694 effects Effects 0.000 claims description 37
- 208000026310 Breast neoplasm Diseases 0.000 claims description 35
- 206010006187 Breast cancer Diseases 0.000 claims description 34
- 229940011871 estrogen Drugs 0.000 claims description 31
- 239000000262 estrogen Substances 0.000 claims description 31
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 31
- 102000005962 receptors Human genes 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- 239000002552 dosage form Substances 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 125000005549 heteroarylene group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 125000000732 arylene group Chemical group 0.000 claims description 19
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 19
- 230000002195 synergetic effect Effects 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 15
- 201000005202 lung cancer Diseases 0.000 claims description 15
- 208000020816 lung neoplasm Diseases 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 8
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 4
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 230000003405 preventing effect Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 description 154
- 125000004093 cyano group Chemical group *C#N 0.000 description 95
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 74
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 66
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 64
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 63
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 61
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 60
- 201000009030 Carcinoma Diseases 0.000 description 56
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 54
- 201000010099 disease Diseases 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 46
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 41
- 239000003814 drug Substances 0.000 description 35
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 28
- 125000005842 heteroatom Chemical group 0.000 description 28
- 125000004043 oxo group Chemical group O=* 0.000 description 25
- 239000002253 acid Substances 0.000 description 23
- 208000032839 leukemia Diseases 0.000 description 22
- 229910052760 oxygen Inorganic materials 0.000 description 22
- 229960001603 tamoxifen Drugs 0.000 description 22
- 206010039491 Sarcoma Diseases 0.000 description 21
- 239000000328 estrogen antagonist Substances 0.000 description 21
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 21
- 229940046836 anti-estrogen Drugs 0.000 description 20
- 230000001833 anti-estrogenic effect Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- 208000024891 symptom Diseases 0.000 description 19
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 16
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 229910052717 sulfur Inorganic materials 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 229910052710 silicon Inorganic materials 0.000 description 15
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 14
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 14
- 229940088597 hormone Drugs 0.000 description 14
- 239000005556 hormone Substances 0.000 description 14
- 229960003881 letrozole Drugs 0.000 description 14
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 13
- 239000002585 base Substances 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 12
- 230000002124 endocrine Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 239000003886 aromatase inhibitor Substances 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 229960004390 palbociclib Drugs 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000019491 signal transduction Effects 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 10
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 10
- 229960002258 fulvestrant Drugs 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 229960002932 anastrozole Drugs 0.000 description 9
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 9
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 8
- 102000007594 Estrogen Receptor alpha Human genes 0.000 description 8
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 8
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 8
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 230000004663 cell proliferation Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 8
- 229960000255 exemestane Drugs 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 102000001301 EGF receptor Human genes 0.000 description 7
- 108060006698 EGF receptor Proteins 0.000 description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 7
- 229960002584 gefitinib Drugs 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229960002367 lasofoxifene Drugs 0.000 description 7
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 229960004622 raloxifene Drugs 0.000 description 7
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229960005026 toremifene Drugs 0.000 description 7
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 7
- KOQIAZNBAWFSQM-UHFFFAOYSA-N 2-[4-(3-ethynylanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]oxyethanol Chemical compound C=12C=C(OCCO)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KOQIAZNBAWFSQM-UHFFFAOYSA-N 0.000 description 6
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 206010014733 Endometrial cancer Diseases 0.000 description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 229960003437 aminoglutethimide Drugs 0.000 description 6
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 6
- 229940046844 aromatase inhibitors Drugs 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 229950002826 canertinib Drugs 0.000 description 6
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000000973 chemotherapeutic effect Effects 0.000 description 6
- 229960003608 clomifene Drugs 0.000 description 6
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 229960001433 erlotinib Drugs 0.000 description 6
- 229950011548 fadrozole Drugs 0.000 description 6
- 229960004891 lapatinib Drugs 0.000 description 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 6
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 description 6
- 229950008835 neratinib Drugs 0.000 description 6
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 6
- 229960003327 ormeloxifene Drugs 0.000 description 6
- 229960003969 ospemifene Drugs 0.000 description 6
- LUMKNAVTFCDUIE-VHXPQNKSSA-N ospemifene Chemical compound C1=CC(OCCO)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 LUMKNAVTFCDUIE-VHXPQNKSSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- UWXSAYUXVSFDBQ-CYBMUJFWSA-N 4-n-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-n-[(4r)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Chemical compound C[C@@H]1COC(NC=2C=C3C(NC=4C=C(Cl)C(OCC=5SC=CN=5)=CC=4)=NC=NC3=CC=2)=N1 UWXSAYUXVSFDBQ-CYBMUJFWSA-N 0.000 description 5
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 5
- 229940122815 Aromatase inhibitor Drugs 0.000 description 5
- 108091007914 CDKs Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229960004421 formestane Drugs 0.000 description 5
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 201000000079 gynecomastia Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- DFJSJLGUIXFDJP-UHFFFAOYSA-N sapitinib Chemical compound C1CN(CC(=O)NC)CCC1OC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(Cl)=C1F DFJSJLGUIXFDJP-UHFFFAOYSA-N 0.000 description 5
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 5
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 229960005353 testolactone Drugs 0.000 description 5
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 5
- 229960001771 vorozole Drugs 0.000 description 5
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 5
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 4
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 4
- 102000000509 Estrogen Receptor beta Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 4
- 108091007960 PI3Ks Proteins 0.000 description 4
- 102000038030 PI3Ks Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 229950010817 alvocidib Drugs 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 208000003747 lymphoid leukemia Diseases 0.000 description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 4
- 239000004005 microsphere Substances 0.000 description 4
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 4
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 102000006255 nuclear receptors Human genes 0.000 description 4
- 108020004017 nuclear receptors Proteins 0.000 description 4
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 3
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 3
- OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical group C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- 239000005461 Canertinib Substances 0.000 description 3
- 208000009458 Carcinoma in Situ Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 102000006311 Cyclin D1 Human genes 0.000 description 3
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 102100029951 Estrogen receptor beta Human genes 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 description 3
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 3
- 101000928259 Homo sapiens NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 3
- 108010000817 Leuprolide Proteins 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- MVZGYPSXNDCANY-UHFFFAOYSA-N N-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]-6-quinazolinyl]-2-propenamide Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(NC(=O)C=C)=CC=C4N=CN=3)=CC=2)Cl)=C1 MVZGYPSXNDCANY-UHFFFAOYSA-N 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- LSPANGZZENHZNJ-UHFFFAOYSA-N PD-153035 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 LSPANGZZENHZNJ-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- LUJZZYWHBDHDQX-QFIPXVFZSA-N [(3s)-morpholin-3-yl]methyl n-[4-[[1-[(3-fluorophenyl)methyl]indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamate Chemical compound C=1N2N=CN=C(NC=3C=C4C=NN(CC=5C=C(F)C=CC=5)C4=CC=3)C2=C(C)C=1NC(=O)OC[C@@H]1COCCN1 LUJZZYWHBDHDQX-QFIPXVFZSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960001686 afatinib Drugs 0.000 description 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 description 3
- 229960005471 androstenedione Drugs 0.000 description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 description 3
- 230000002280 anti-androgenic effect Effects 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960004562 carboplatin Drugs 0.000 description 3
- OGHNVEJMJSYVRP-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=C1C1=CC=CC=C1N2 OGHNVEJMJSYVRP-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 229960004630 chlorambucil Drugs 0.000 description 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 229940069210 coreg Drugs 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 229950002205 dacomitinib Drugs 0.000 description 3
- 229960000975 daunorubicin Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 238000009261 endocrine therapy Methods 0.000 description 3
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 3
- 229960004671 enzalutamide Drugs 0.000 description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 102000046818 human AR Human genes 0.000 description 3
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 229960004338 leuprorelin Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 208000025113 myeloid leukemia Diseases 0.000 description 3
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 3
- ZYQXEVJIFYIBHZ-UHFFFAOYSA-N n-[2-[4-[3-chloro-4-[3-(trifluoromethyl)phenoxy]anilino]pyrrolo[3,2-d]pyrimidin-5-yl]ethyl]-3-hydroxy-3-methylbutanamide Chemical compound C=12N(CCNC(=O)CC(C)(O)C)C=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OC1=CC=CC(C(F)(F)F)=C1 ZYQXEVJIFYIBHZ-UHFFFAOYSA-N 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 229950006299 pelitinib Drugs 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229950003687 ribociclib Drugs 0.000 description 3
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 3
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 description 3
- TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 3
- 229960000241 vandetanib Drugs 0.000 description 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 2
- STUWGJZDJHPWGZ-GFCCVEGCSA-N (2R)-1-N-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@@H]1C(N)=O STUWGJZDJHPWGZ-GFCCVEGCSA-N 0.000 description 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- QFWCYNPOPKQOKV-UHFFFAOYSA-N 2-(2-amino-3-methoxyphenyl)chromen-4-one Chemical compound COC1=CC=CC(C=2OC3=CC=CC=C3C(=O)C=2)=C1N QFWCYNPOPKQOKV-UHFFFAOYSA-N 0.000 description 2
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 description 2
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 2
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- HFPLHASLIOXVGS-UHFFFAOYSA-N 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione Chemical compound S1C(C)=NC(C2=O)=C1C(=O)C=C2NC1=CC=C(C)C=C1 HFPLHASLIOXVGS-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 2
- BBUVDDPUURMFOX-SAABIXHNSA-N AMG-925 Chemical compound C1C[C@@H](C)CC[C@@H]1N1C2=NC(NC=3N=C4CCN(CC4=CC=3)C(=O)CO)=NC=C2C2=CC=NC=C21 BBUVDDPUURMFOX-SAABIXHNSA-N 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 2
- LLVZBTWPGQVVLW-SNAWJCMRSA-N CP-724714 Chemical compound C12=CC(/C=C/CNC(=O)COC)=CC=C2N=CN=C1NC(C=C1C)=CC=C1OC1=CC=C(C)N=C1 LLVZBTWPGQVVLW-SNAWJCMRSA-N 0.000 description 2
- 206010008583 Chloroma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- OTPNDVKVEAIXTI-UHFFFAOYSA-N LSM-1274 Chemical compound C12=C3C4=C5C=CC=C[C]5N3C(O3)CCC3N2C2=CC=C[CH]C2=C1C1=C4C(=O)NC1=O OTPNDVKVEAIXTI-UHFFFAOYSA-N 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 201000001542 Schneiderian carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- DVEXZJFMOKTQEZ-JYFOCSDGSA-N U0126 Chemical compound C=1C=CC=C(N)C=1SC(\N)=C(/C#N)\C(\C#N)=C(/N)SC1=CC=CC=C1N DVEXZJFMOKTQEZ-JYFOCSDGSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- GGQCIOOSELPMBB-UHFFFAOYSA-N [3-[[6-(2-methoxyphenyl)pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound COC1=CC=CC=C1C1=CC(NC=2C=C(CS(N)(=O)=O)C=CC=2)=NC=N1 GGQCIOOSELPMBB-UHFFFAOYSA-N 0.000 description 2
- ROCFOIBAEVAOLQ-UHFFFAOYSA-N [5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol Chemical compound O1C(C)=CC=C1CNC1=NC=NC2=CC=C(C=3OC(CO)=CC=3)C=C12 ROCFOIBAEVAOLQ-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229960000684 cytarabine Drugs 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
- 229960001348 estriol Drugs 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- PWUOOJVYZQILBG-UHFFFAOYSA-N fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 229950007440 icotinib Drugs 0.000 description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 2
- IFSDAJWBUCMOAH-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 IFSDAJWBUCMOAH-HNNXBMFYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000005987 myeloid sarcoma Diseases 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000004175 parthenolide derivatives Chemical class 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960002087 pertuzumab Drugs 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 2
- 208000031223 plasma cell leukemia Diseases 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000003207 proteasome inhibitor Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- ZKDXRFMOHZVXSG-HNNXBMFYSA-N purvalanol B Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)C(C)C)=NC=1NC1=CC=C(C(O)=O)C(Cl)=C1 ZKDXRFMOHZVXSG-HNNXBMFYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 2
- 229950006474 sapitinib Drugs 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 102000009076 src-Family Kinases Human genes 0.000 description 2
- 108010087686 src-Family Kinases Proteins 0.000 description 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- QNUKRWAIZMBVCU-WCIBSUBMSA-N su9516 Chemical compound C12=CC(OC)=CC=C2NC(=O)\C1=C/C1=CN=CN1 QNUKRWAIZMBVCU-WCIBSUBMSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960004066 trametinib Drugs 0.000 description 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 229950006605 varlitinib Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- JRNJNYBQQYBCLE-UHFFFAOYSA-N (4-amino-2-{[1-(methylsulfonyl)piperidin-4-yl]amino}pyrimidin-5-yl)(2,3-difluoro-6-methoxyphenyl)methanone Chemical compound COC1=CC=C(F)C(F)=C1C(=O)C(C(=N1)N)=CN=C1NC1CCN(S(C)(=O)=O)CC1 JRNJNYBQQYBCLE-UHFFFAOYSA-N 0.000 description 1
- SCFMWQIQBVZOQR-UHFFFAOYSA-N (4-butoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)-(2,6-difluoro-4-methylphenyl)methanone Chemical compound C1=NC=2NN=CC=2C(OCCCC)=C1C(=O)C1=C(F)C=C(C)C=C1F SCFMWQIQBVZOQR-UHFFFAOYSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- UQVNRKBFAXNOGA-LWTNMJDUSA-N (E)-tomaymycin Chemical compound CO[C@H]1NC2=CC(O)=C(OC)C=C2C(=O)N2C\C(=C\C)C[C@@H]12 UQVNRKBFAXNOGA-LWTNMJDUSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- QLUYMIVVAYRECT-OCCSQVGLSA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O QLUYMIVVAYRECT-OCCSQVGLSA-N 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- MHXVDXXARZCVRK-WCWDXBQESA-N 2-[2-[4-[(e)-3,3,3-trifluoro-1,2-diphenylprop-1-enyl]phenoxy]ethylamino]ethanol Chemical compound C1=CC(OCCNCCO)=CC=C1C(\C=1C=CC=CC=1)=C(C(F)(F)F)/C1=CC=CC=C1 MHXVDXXARZCVRK-WCWDXBQESA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 description 1
- YVXCDLCJCIDFHE-UHFFFAOYSA-N 4-[[6-(ethylamino)-2-[[1-(phenylmethyl)-5-indolyl]amino]-4-pyrimidinyl]amino]-1-cyclohexanol Chemical compound N=1C(NC=2C=C3C=CN(CC=4C=CC=CC=4)C3=CC=2)=NC(NCC)=CC=1NC1CCC(O)CC1 YVXCDLCJCIDFHE-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- JEGHXKRHKHPBJD-UHFFFAOYSA-N 5-(7-methylsulfonyl-2-morpholin-4-yl-5,6-dihydropyrrolo[2,3-d]pyrimidin-4-yl)pyrimidin-2-amine Chemical compound CS(=O)(=O)N1CCC2=C1N=C(N1CCOCC1)N=C2C1=CN=C(N)N=C1 JEGHXKRHKHPBJD-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- XXSSGBYXSKOLAM-UHFFFAOYSA-N 5-bromo-n-(2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzamide Chemical compound OCC(O)CONC(=O)C1=CC(Br)=C(F)C(F)=C1NC1=CC=C(I)C=C1F XXSSGBYXSKOLAM-UHFFFAOYSA-N 0.000 description 1
- YHSMSRREJYOGQJ-UHFFFAOYSA-N 5-nonyloxytryptamine Chemical compound CCCCCCCCCOC1=CC=C2NC=C(CCN)C2=C1 YHSMSRREJYOGQJ-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LMJFJIDLEAWOQJ-CQSZACIVSA-N 8-[(1r)-1-(3,5-difluoroanilino)ethyl]-n,n-dimethyl-2-morpholin-4-yl-4-oxochromene-6-carboxamide Chemical compound N([C@H](C)C=1C2=C(C(C=C(O2)N2CCOCC2)=O)C=C(C=1)C(=O)N(C)C)C1=CC(F)=CC(F)=C1 LMJFJIDLEAWOQJ-CQSZACIVSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000035805 Aleukaemic leukaemia Diseases 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- YUXMAKUNSXIEKN-BTJKTKAUSA-N BGT226 Chemical compound OC(=O)\C=C/C(O)=O.C1=NC(OC)=CC=C1C1=CC=C(N=CC2=C3N(C=4C=C(C(N5CCNCC5)=CC=4)C(F)(F)F)C(=O)N2C)C3=C1 YUXMAKUNSXIEKN-BTJKTKAUSA-N 0.000 description 1
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical compound C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000013165 Bowen disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- 101100219189 Caenorhabditis elegans byn-1 gene Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 101710196141 Estrogen receptor Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 229940123502 Hormone receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- CZQHHVNHHHRRDU-UHFFFAOYSA-N LY294002 Chemical compound C1=CC=C2C(=O)C=C(N3CCOCC3)OC2=C1C1=CC=CC=C1 CZQHHVNHHHRRDU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010053180 Leukaemia cutis Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- ULDXWLCXEDXJGE-UHFFFAOYSA-N MK-2206 Chemical compound C=1C=C(C=2C(=CC=3C=4N(C(NN=4)=O)C=CC=3N=2)C=2C=CC=CC=2)C=CC=1C1(N)CCC1 ULDXWLCXEDXJGE-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 102100022165 Nuclear factor 1 B-type Human genes 0.000 description 1
- 101710170464 Nuclear factor 1 B-type Proteins 0.000 description 1
- 229910003849 O-Si Inorganic materials 0.000 description 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910003872 O—Si Inorganic materials 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 1
- 101150001535 SRC gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000275021 Sesbania grandiflora Species 0.000 description 1
- 235000015392 Sesbania grandiflora Nutrition 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- UQVNRKBFAXNOGA-IUODEOHRSA-N Tomaymycin Natural products CO[C@H]1Nc2cc(O)c(OC)cc2C(=O)N3CC(=CC)C[C@H]13 UQVNRKBFAXNOGA-IUODEOHRSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 1
- 229950001573 abemaciclib Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005238 alkylenediamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 230000002707 ameloblastic effect Effects 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- ACPOUJIDANTYHO-UHFFFAOYSA-N anthra[1,9-cd]pyrazol-6(2H)-one Chemical compound C1=CC(C(=O)C=2C3=CC=CC=2)=C2C3=NNC2=C1 ACPOUJIDANTYHO-UHFFFAOYSA-N 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000016894 basaloid carcinoma Diseases 0.000 description 1
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- ZWVZORIKUNOTCS-OAQYLSRUSA-N chembl401930 Chemical compound C1([C@H](O)CNC2=C(C(NC=C2)=O)C=2NC=3C=C(C=C(C=3N=2)C)N2CCOCC2)=CC=CC(Cl)=C1 ZWVZORIKUNOTCS-OAQYLSRUSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 201000011050 comedo carcinoma Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000011063 cribriform carcinoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 238000001678 elastic recoil detection analysis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 230000008556 epithelial cell proliferation Effects 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 1
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 etanidazole Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000038004 exacerbated respiratory disease Diseases 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000017750 granulocytic sarcoma Diseases 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 239000003689 hormone receptor blocking agent Substances 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000011941 human estrogen receptor alpha Human genes 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 101150030475 impact gene Proteins 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229940126401 izorlisib Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- YACHGFWEQXFSBS-RJXCBBHPSA-N leptomycin Chemical class OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)\C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-RJXCBBHPSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 108010093470 monomethyl auristatin E Proteins 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical class CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- AARXZCZYLAFQQU-UHFFFAOYSA-N motexafin gadolinium Chemical compound [Gd].CC(O)=O.CC(O)=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 AARXZCZYLAFQQU-UHFFFAOYSA-N 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229940125745 nitric oxide modulator Drugs 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 208000029809 non-keratinizing sinonasal squamous cell carcinoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229950003440 panomifene Drugs 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009682 proliferation pathway Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000003881 protein kinase C inhibitor Substances 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 229950009919 saracatinib Drugs 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 208000004259 scirrhous adenocarcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- 229950010746 selumetinib Drugs 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 229950008834 seribantumab Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000011584 spitz nevus Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 201000010033 subleukemic leukemia Diseases 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 208000008662 verrucous carcinoma Diseases 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Breast cancer is the most common malignancyin women in NorthAmerica.Eachyear more than 210,000 new cases ofbreast cancer are diagnosed in the US (1-3).In the clinic, endocrine therapyis an important intervention for cancers that express estrogen receptor (ER), and it has proven to be one ofthe most effective treatment strategies for breast cancer (3,4).At diagnosis, about 70% ofbreast cancers contain estrogen receptors and depend on estrogen for growthand progression.Expression ofER in a tumor is predictive ofa clinical response to hormonal therapy.Suchobservations have led to current use ofantiestrogens (suchas fulvestrant, tamoxifen and its relatives, raloxifene, toremifene, lasofoxifene, etc.)and aromatase inhibitors in treating ER-positive breast cancer (2,3).Tamoxifen and its analogues are among the most highly prescribed drugs for initial estrogen-dependent breast cancer.However, theyare not without their drawbacks since theybind to the estrogen receptor in manyt
- Estrogen modulates gene transcription in breast cancers throughits receptors using different signaling pathways (2,8)(see FIG.1).
- the classical pathwayinvolves direct DNA binding of liganded receptor to estrogen response elements (EREs)in the promoter regions ofresponsive genes.
- E2 estrogen response elements
- ER estrogen receptor
- ER ⁇ generally considered most important in tumor progression (5,6,9).
- ER ⁇ has 6 major functional domains including an N-terminal transactivation domain, an adjacent DNA-binding domain and a C-terminal portion involved in hormone-binding, receptor dimerization and activity of a second transactivation region.
- E2 binds ER to promote dimerization and phosphorylation ofthe receptor. This allows direct binding ofthe ligand-ER complexwithsteroid receptor coactivators (CoReg)and E2-responsive elements (ERE)in DNA, leading to changes in gene transcription that regulate growth, differentiation, apoptosis and angiogenesis.
- CoReg the ligand-ER complexwithsteroid receptor coactivators
- ERP E2-responsive elements
- a subset ofER associate with extranuclear sites and interact there withmembrane growthfactor receptors (EGFR, HER2)and other signaling molecules (components ofthe ras-MAPK and PI3K/AKTpathways, Shc
- ER often continues to playa major role in controlling growthofhormone-resistant cancers.
- AI antiaromatase inhibitors
- ER activation byalternate ligands local E2 production and development ofER hypersensitivityare especiallyproblematic (2,6).
- ligand-independent activation ofER occurs in tumors overexpressing growthfactor receptors suchas HER2, withgrowthfactor receptors promoting ER phosphorylation even in the absence ofestrogen (5,9,11).Suchligand-independent mechanisms likelycontribute to resistance to AI’s as well as antiestrogens (12,13).
- These nonclassical events are mediated byER or adaptor proteins that impact gene expression indirectlybyactivating growth-promoting kinase cascades to regulate transcription.
- breast tumors significant evidence suggests that regulation ofboth proliferation and cell deathpathways occurs, in part, bythe action ofnonclassical kinase- mediated pathways (9,11,14-19).Better understanding and targeting ofthese complexsignaling pathways in
- ER degradation limits hormone action.Ligand-induced down-regulation ofER is a pivotal step in halting E2 stimulation ofgrowth, and the ubiquitin–proteasome pathwayis the major system for selective degradation of such regulatory proteins (30). ER ⁇ was among the first ofthe nuclear receptors identified as substrates for this pathway(31-34).A common feature of proteasome-mediated protein degradation is covalent attachment ofubiquitin to lysine residues of proteins targeted for degradation followed byformation ofpolyubiquitin chains attached covalently to the protein.
- Ubiquitinated ER ⁇ is recognized and degraded by the multisubunit protease complex, the 26S proteasome (35).ER is degraded in a hormone-dependent manner, withthis process contributing to regulation ofhormone action;and the proteasome inhibitor, MG132, is well known to promote invivo accumulation ofER and to blockligand-induced ER degradation (33).As noted above, the proteasome pathwayalso plays a critical role in interaction ofER withantagonists, suchas SERMs and fulvestrant (27, 34).
- composition including a CDK4 inhibitor or a CDK6 inhibitor and a compound, or a pharmaceuticallyacceptable salt thereof, having the formula (I):
- R 1 is independentlya hydrogen, halogen, -NR 2 R 3 , -CX a
- R 2 is independentlya hydrogen
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 4 is independentlya hydrogen, halogen, -CX d
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independently hydrogen, halogen, -CX 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, - SO 4 H,
- n is an integer from 0 to 5.
- the symbols m1, m2, m3, m4, v1, v2, v3, and v4 are independently1 or 2.
- the symbols n1, n2, n3, and n4 are independentlyan integer from 0 to 4.
- the symbols X, X a , X b , X c and X d are independently–Cl, -Br, -I, or -F.
- a kit including a CDK4 inhibitor or a CDK6 inhibitor, and a compound having the structure ofFormula (I)as disclosed herein, or pharmaceutically acceptable salt thereof.
- a method oftreating a hyperproliferative disorder in a subject in need thereof including administering to the subject an effective amount of a composition as disclosed herein, or the compound and the CDK4 inhibitor or CDK6 inhibitor of a kit as disclosed herein.
- a method ofinhibiting estrogen receptor activityin a subject in need thereof including administering to the subject an effective amount of a composition as disclosed herein, or the compound and the CDK4 inhibitor or CDK6 inhibitor of a kit as disclosed herein.
- FIG.S. Interactions ofestrogen and growthfactor receptor signaling pathways in cancer cells.
- FIG.S2.Antiestrogen JD140 elicits enhanced PARP cleavage in NSCLC cells.A549 cells were treated in 5% DCC-FBS phenol-red free RPMI1640 withvehicle control (C)or increasing concentrations ofJD140 at 0.01, 0.1 and 1 ⁇ M or 0.1 ⁇ M fulvestrant (F)for 4 hours. W estern Blots were performed using anti-cleaved-PARP antibody(Cell Signaling Technology). RPL13A is shown as loading control. The W estern blot is representative of3 independent experiments.
- FIG.3.Estrogen receptor-alpha is down-regulated byantiestrogens.
- FIG.S3.Tumor cell cycle regulation byCDK 4/6 and cyclin D The cell cycle clock machinery.G0, M, G1, S and G2 refer to quiescence, mitosis, first gap, DNA synthesis and 2nd gap phases ofthe cell cycle, respectively.
- the restriction point (R-Point)is shown.Rb and Rb-p represent unphosphorylated and hyper-phosphorylated forms ofretinoblastoma (Rb)protein that regulates the cell cycle;modified from Lundberg & W einberg Eur JCancer.1999;35:1886).
- FIGS.4A-4B.MCF-7 cells withacquired tamoxifen resistance show increased expression ofHER-1/EGFR and HER-2 receptors.
- FIG.S4.Palbociclib in combination withletrozole blocks phosphorylation ofRb serine-780 in A549 cells.Cells were treated 24 hin phenol red-free RPMIwith1% DCC-FBS with vehicle control (CON), 1 nM estradiol-17 ⁇ (E2), 1 nM androstenedione (And), 10 nM testosterone (Tes), 10 ⁇ M letrozole (AI), 100 nM palbociclib (Plbo) or both Plbo + AI.
- FIG.5. Specific binding of[3H]estradiol-17 ⁇ byMCF-7 parental breast cancer cells is suppressed byERD compound 15 (JD105).
- Compounds S1-S14 in the present figure are comparative test compounds (different from individual compounds described herein)showing less inhibition than compound S15 in the present assay.
- FIG.S5.Letrozole (AI)byblocking estrogen signaling reduces cyclin D1 expression in A549 NSCLC cells using W estern immunoblot methods.Cells were treated 24 hin phenol red-free RPMIwith1% DCC-FBS.Control (Con), estradiol-17 ⁇ (E2;1 nM), androstenedione (And;1 nM), testosterone (Tst;10 nM), letrozole (AI;10 ⁇ M)and palbociclib (Plbo;1 ⁇ M)were used in this experiment.GADPH is used as a loading control (20). [0029] FIG.6.ERD S15 reduces ER protein levels in MCF-7 breast tumor cells.
- FIG.S6.Palbociclib and letrozole dosed as single agents and combined as a dual therapyinvitro in human NSCLC cells A549.Eachdrug elicits dose-dependent inhibition of NSCLC cell proliferation as compared to controls when administered for 72 hrs.However, treatment witha combination ofeither palbociclib (10-nM)/letrozole (10- ⁇ M)[10P/10L]or palbociclib (100nM)/ letrozole (10 ⁇ M)[100P/10L]for 72 hinvitro elicits enhanced inhibition ofcell proliferation ofNSCLC cells, indicating potential synergyin dual therapy.This finding corresponds to the synergistic interaction ofpalbociclib withantiestrogen agents that was previouslyreported in hormone receptor-positive human breast cancer cells under invitro conditions [19,20].
- FIG.S7.SERD 128 down-regulates cyclin D1 in MCF-7 breast cancer cells.W estern immunoblot of cyclin D1 after treating MCF-7 cells 24 hrs with 10% FBS and 1 ⁇ M and 10 ⁇ M doses ofJD105, JD128 and JD140.Refer to FIG.S4 methods and previous reports (20).
- FIG.8.Novel antiestrogen JD140 elicits significant antiproliferative effects in human non-small cell lung cancer cells A549 as compared withthe activityoffulvestrant.
- FIG.S8.SERD compounds in combination withthe CDK 4/6 inhibitor palbociclib blocks NSCLC cell proliferation invitro.In panel (a), NSCLC cells were treated with palbociclib alone at 1 ⁇ M.In panel (b), tumor NSCLC cells were treated withSERD compounds 103,140 or 160 alone at a dose of10 ⁇ M.In panel (c), NSCLC cells are treated witha combination ofpalbociclib at 1 ⁇ M withSERD compounds indicated in the figure at 10 ⁇ M.See methods below.Mean cell proliferation values +SE are shown as % controls.
- FIG.9 Activation of estrogen receptor (ER) by estradiol-17 ⁇ or by growth factor receptor signaling promotes gene transcription for tumor cell proliferation and inhibition of apoptosis.Disruption byselective estrogen receptor downregulators ofcritical steps in these pathways includes downstream actions suchas modulation ofcyclin D expression in the control ofthe cell cycle and proliferation and regulation ofapoptosis.
- ER estrogen receptor
- FIG.10 S128 in combination withpalbociclib (Pb), a CDK4/CDK6 inhibitor, blocks endocrine-resistant breast cancer (BC)cell proliferation invitro.
- W here substituent groups are specified bytheir conventional chemical formulae, written from left to right, theyequallyencompass the chemicallyidentical substituents that would result from writing the structure from right to left, e.g., -CH 2 O- is equivalent to -OCH 2 -.
- alkyl byitselfor as part ofanother substituent, means, unless otherwise stated, a straight (i.e., unbranched)or branched non-cyclic carbon chain (or carbon), or combination thereof, whichmaybe fullysaturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number ofcarbon atoms designated (i.e., C 1 -C 10 means one to ten carbons).
- examples ofsaturated hydrocarbon radicals include, but are not limited to, groups suchas methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl,
- cyclohexyl (cyclohexyl)methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2- isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3- butynyl, and the higher homologs and isomers.
- An alkoxy is an alkyl attached to the remainder ofthe molecule via an oxygen linker (-O-).
- An alkyl moiety maybe an alkenyl moiety.
- An alkyl moiety maybe an alkynyl moiety.
- alkyl moiety maybe fullysaturated.
- alkylene byitselfor as part ofanother substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited
- alkyl (or alkylene)group will have from 1 to 24 carbon atoms, withthose groups having 10 or fewer carbon atoms being preferred in the present invention.
- A“lower alkyl”or“lower alkylene” is a shorter chain alkyl or alkylene group, generallyhaving eight or fewer carbon atoms.
- alkenylene byitselfor as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
- heteroalkyl byitselfor in combination withanother term, means, unless otherwise stated, a stable non-cyclic straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g.O, N, P, Si, and S)and wherein the nitrogen and sulfur atoms mayoptionallybe oxidized, and the nitrogen heteroatom mayoptionallybe quaternized.
- the heteroatom(s)(e.g.O, N, P, S, and Si) maybe placed at any interior position ofthe heteroalkyl group or at the position at whichthe alkyl group is attached to the remainder ofthe molecule.
- examples include, but are not limited
- heteroalkylene means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
- heteroalkylene groups heteroatoms can also occupyeither or bothofthe chain termini (e.g.,alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).Still further, for alkylene and heteroalkylene linking groups, no orientation ofthe linking group is implied bythe direction in whichthe formula ofthe linking group is written.For example, the formula -C(O) 2 R'- represents both-C(O) 2 R'- and -R'C(O) 2 -.As described above, heteroalkyl groups, as
- heteroalkyl should not be interpreted herein as excluding specific heteroalkyl groups, suchas -NR'R'or the like.
- a heteroatom can occupythe position at whichthe heterocycle is attached to the remainder ofthe molecule.
- Examples ofcycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohe
- halo or“halogen,”bythemselves or as part ofanother substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- terms such as“haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl.
- halo(C 1 -C 4 )alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- acyl means, unless otherwise stated, -C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- aryl a polyunsaturated, aromatic, hydrocarbon substituent, whichcan be a single ring or multiple rings (preferablyfrom 1 to 3 rings)that are fused together (i.e., a fused ring aryl)or linked covalently.
- a fused ring aryl refers to multiple rings fused together wherein at least one ofthe fused rings is an aryl ring.
- the term “heteroaryl” refer to aryl groups (or rings)that contain at least one heteroatom suchas N, O, or S, wherein the nitrogen and sulfur atoms are optionallyoxidized, and the nitrogen atom(s)are optionallyquaternized.
- a 5,6-fused ring heteroarylene refers to two rings fused together, wherein
- aryl and heteroaryl ring systems are selected from the group ofacceptable substituents described below.
- An“arylene”and a“heteroarylene,”alone or as part ofanother substituent mean a divalent radical derived from an aryl and heteroaryl, respectively.
- Non-limiting examples ofaryl and heteroaryl groups include pyridinyl,
- a fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl.
- a fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl.
- a fused ring heterocyloalkyl-aryl is an aryl fused to a heterocycloalkyl.
- a fused ring heterocycloalkyl-heteroaryl is a heteroaryl fused to a heterocycloalkyl.
- heterocycloalkyl-cycloalkyl is a heterocycloalkyl fused to a cycloalkyl.A fused ring
- heterocycloalkyl-heterocycloalkyl is a heterocycloalkyl fused to another heterocycloalkyl.Fused ring heterocycloalkyl-aryl, fused ring heterocycloalkyl-heteroaryl, fused ring heterocycloalkyl- cycloalkyl, or fused ring heterocycloalkyl-heterocycloalkyl mayeachindependentlybe unsubstituted or substituted withone or more ofthe substituents described herein. [0051]
- the term“oxo,”as used herein, means an oxygen that is double bonded to a carbon atom.
- alkylsulfonyl means a moietyhaving the formula -S(O 2 )-R', where R'is a substituted or unsubstituted alkyl group as defined above.R'mayhave a specified number ofcarbons (e.g.,“C 1 -C 4 alkylsulfonyl”).
- -NR'C (O)NR'NR''R'', -CN, -NO 2 , in a number ranging from zero to (2m'+1), where m'is the total number ofcarbon atoms in suchradical.R, R', R', R'', and R''eachpreferably
- unsubstituted aryl e.g., aryl substituted with1-3 halogens
- substituted or unsubstituted heteroaryl substituted or unsubstituted alkyl, alkoxy, or thioalkoxygroups, or arylalkyl groups.
- W hen a compound ofthe invention includes more than one R group, for example, eachofthe R groups is independentlyselected as are eachR', R', R'', and R''group when more than one of these groups is present.
- W hen R'and R' are attached to the same nitrogen atom, theycan be combined withthe nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring.
- -NR'R' includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl.
- the term“alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, suchas haloalkyl (e.g., -CF 3 and -CH 2 CF 3 )and acyl (e.g., -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
- -NR'C (O)NR'NR''R'', -CN, -NO 2 , -R', -N 3 , -CH(Ph) 2 , fluoro(C 1 -C 4 )alkoxy, and fluoro(C 1 - C 4 )alkyl, in a number ranging from zero to the total number ofopen valences on the aromatic ring system;and where R', R', R'', and R''are preferablyindependentlyselected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or
- a compound ofthe invention includes more than one R group, for example, eachofthe R groups is independently selected as are eachR', R', R'', and R''groups when more than one ofthese groups is present.
- Two or more substituents mayoptionallybe joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
- ring-forming substituents are typically, thoughnot necessarily, found attached to a cyclic base structure.
- the ring-forming substituents are attached to adjacent members ofthe base structure.
- two ring-forming substituents attached to adjacent members ofa cyclic base structure create a fused ring structure.
- the ring-forming substituents are attached to a single member ofthe base structure.
- two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
- the ring- forming substituents are attached to non-adjacent members ofthe base structure.
- Two ofthe substituents on adjacent atoms ofthe aryl or heteroaryl ring mayoptionally form a ring ofthe formula -T-C(O)-(CRR') q -U-, wherein Tand U are
- two ofthe substituents on adjacent atoms ofthe aryl or heteroaryl ring may optionallybe replaced with a substituent ofthe formula -A-(CH 2 ) r -B-, wherein A and B are independently-CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O) 2 -, -S(O) 2 NR'-, or a single bond, and r is an integer offrom 1 to 4.
- One ofthe single bonds ofthe new ring so formed mayoptionallybe replaced witha double bond.
- two ofthe substituents on adjacent atoms ofthe aryl or heteroaryl ring mayoptionallybe replaced witha substituent ofthe
- R, R', R', and R'' are preferablyindependentlyselected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- heterocycloalkyl unsubstituted aryl, unsubstituted heteroaryl, and (b)alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted with at least one substituent selected from: oxo,
- A“size-limited substituent”or“size-limited substituent group,”as used herein, means a group selected from all ofthe substituents described above for a“substituent group,”wherein eachsubstituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, eachsubstituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl, eachsubstituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, eachsubstituted or unsubstituted or unsubstituted or unsubstituted or unsubstituted
- A“lower substituent”or“lower substituent group,”as used herein, means a group selected from all ofthe substituents described above for a“substituent group,”wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl, eachsubstituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, eachsubstituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl, and eachsubstituted or
- eachsubstituted group described in the compounds herein is substituted withat least one substituent group.
- each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted withat least one substituent group.
- at least one or all ofthese groups are substituted withat least one size-limited substituent group.
- at least one or all ofthese groups are substituted withat least one lower substituent group.
- eachsubstituted or unsubstituted alkyl maybe a substituted or unsubstituted C 1 -C 20 alkyl
- eachsubstituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl
- eachsubstituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 8 cycloalkyl
- eachsubstituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl
- each substituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
- each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
- eachsubstituted or unsubstituted alkyl is a substituted or unsubstituted C 1 -C 8 alkyl
- eachsubstituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl
- eachsubstituted or unsubstituted cycloalkyl is a substituted or unsubstituted C 3 -C 7 cycloalkyl
- eachsubstituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl
- eachsubstituted or unsubstituted aryl is a substituted or unsubstituted C 6 -C 10 aryl
- eachsubstituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
- salts ofthe active compounds that are prepared withrelativelynontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form ofsuchcompounds witha sufficient amount ofthe desired base, either neat or in a suitable inert solvent.
- examples ofpharmaceuticallyacceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained bycontacting the neutral form ofsuchcompounds witha sufficient amount ofthe desired acid, either neat or in a suitable inert solvent.
- pharmaceuticallyacceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric,
- the compounds ofthe present invention mayexist as salts, suchas with pharmaceuticallyacceptable acids.
- the present invention includes suchsalts.
- Such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (e.g., (+)-tartrates, (-)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts withamino acids suchas glutamic acid.
- These salts maybe prepared bymethods known to those skilled in the art.
- the neutral forms ofthe compounds are preferablyregenerated bycontacting the salt witha base or acid and isolating the parent compound in the conventional manner.
- the parent form ofthe compound differs from the various salt forms in certain physical properties, suchas solubilityin polar solvents.
- agents e.g.compounds, drugs, therapeutic agents
- Prodrugs ofthe compounds described herein are those compounds that readily undergo chemical changes under select physiological conditions to provide the final agents (e.g. compounds, drugs, therapeutic agents).
- prodrugs can be converted to agents (e.g.
- Prodrugs described herein include compounds that readilyundergo chemical changes under select physiological conditions to provide agents (e.g.compounds, drugs, therapeutic agents)to a biological system (e.g.in a subject, in a cancer cell, in the extracellular space near a cancer cell).
- Certain compounds ofthe present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms.In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope ofthe present invention.Certain compounds ofthe present invention mayexist in multiple crystalline or amorphous forms.In general, all physical forms are equivalent for the uses contemplated bythe present invention and are intended to be within the scope ofthe present invention.
- salt refers to acid or base salts ofthe compounds used in the methods ofthe present invention.
- Acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like)salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like)salts, quaternaryammonium (methyl iodide, ethyl iodide, and the like)salts.
- Certain compounds ofthe present invention possess asymmetric carbon atoms (optical or chiral centers)or double bonds;the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that maybe defined, in terms ofabsolute
- the term“isomers” refers to compounds having the same number and kind ofatoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration ofthe atoms.
- the term“tautomer,”as used herein, refers to one oftwo or more structural isomers whichexist in equilibrium and whichare readilyconverted from one isomeric form to another.
- certain compounds ofthis invention may exist in tautomeric forms, all suchtautomeric forms ofthe compounds being within the scope of the invention.
- structures depicted herein are also meant to include all stereochemical forms ofthe structure;i.e., the R and S configurations for eachasymmetric center.Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures ofthe present compounds are within the scope ofthe invention.
- structures depicted herein are also meant to include compounds whichdiffer onlyin the presence ofone or more isotopicallyenriched atoms.For example, compounds having the present structures except for the replacement ofa hydrogen bya deuterium or tritium, or the replacement ofa carbon by 13 C- or 14 C-enriched carbon are within the scope ofthis invention.
- the compounds ofthe present invention may also contain unnatural proportions of atomic isotopes at one or more ofthe atoms that constitute suchcompounds.
- the compounds maybe radiolabeled withradioactive isotopes, suchas for example tritium ( 3 H), iodine-125 ( 125 I), or carbon-14 ( 14 C). All isotopic variations ofthe compounds ofthe present invention, whether radioactive or not, are encompassed within the scope ofthe present invention.
- the symbol“ ” denotes the point ofattachment ofa chemical moietyto the remainder ofa molecule or chemical formula.
- the terms“treating”or“treatment” refers to anyindicia ofsuccess in the treatment or amelioration ofan injury, disease, pathologyor condition, including anyobjective or subjective parameter suchas abatement;remission;diminishing ofsymptoms or making the injury, pathologyor condition more tolerable to the patient;slowing in the rate ofdegeneration or decline;making the final point ofdegeneration less debilitating;improving a patient’s physical or mental well-being.
- the treatment or amelioration ofsymptoms can be based on objective or subjective parameters;including the results ofa physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
- certain methods herein treat diseases associated withestrogen receptor activity.Certain methods described herein maytreat diseases associated withestrogen receptor activity(e.g., breast cancer, lung cancer, a gynecological cancer, ovarian cancer, endometrial cancer, or prostate cancer, lymphangioleiomyomatosis (LAM)
- Certain methods described herein maytreat diseases associated withhyperproliferation (e.g., of cells).For example, certain methods herein treat cancer.For example certain methods herein treat cancer bydecreasing a symptom ofcancer.Symptoms ofcancer would be known or may be determined bya person ofordinaryskill in the art. The term “treating” and conjugations thereof, include prevention ofinjury, pathology, condition, or disease. [0082] An“effective amount”is an amount sufficient to accomplisha stated purpose (e.g.
- an“effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms ofa disease, whichcould also be referred to as a“therapeuticallyeffective amount.”
- A“prophylacticallyeffective amount”ofa drug or prodrug is an amount ofa drug or prodrug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence)ofan injury, disease, pathologyor condition, or reducing the likelihood ofthe onset (or reoccurrence)ofan injury, disease, pathology, or condition, or their symptoms.
- the full prophylactic effect does not necessarilyoccur byadministration of
- the term“associated”or“associated with”in the context of a substance or substance activityor function associated witha disease e.g.hyperproliferative disease, cancer
- a disease associated withestrogen receptor activity maybe treated withan agent (e.g.compound as described herein)effective for decreasing the level ofestrogen receptor activity.
- Control or“control experiment”or“standard control”is used in accordance withits plain ordinary meaning and refers to an experiment in whichthe subjects or reagents ofthe experiment are treated as in a parallel experiment except for omission ofa procedure, reagent, or variable ofthe experiment.In some instances, the control is used as a standard ofcomparison in evaluating experimental effects.
- Contacting is used in accordance withits plain ordinary meaning and refers to the process ofallowing at least two distinct species (e.g.chemical compounds including
- biomolecules, or cells to become sufficientlyproximal to react, interact or physicallytouch.
- the resulting reaction product can be produced directlyfrom a reaction between the added reagents or from an intermediate from one or more ofthe added reagents whichcan be produced in the reaction mixture.
- the term“contacting” mayinclude allowing two species to react, interact, or physicallytouch, wherein the two species maybe a compound as described herein and a protein or enzyme. In some embodiments contacting includes allowing a compound described herein to interact witha protein or enzyme.
- inhibition means negativelyaffecting (e.g.decreasing)the level ofactivityor function ofthe protein relative to the level ofactivityor function ofthe protein in the absence ofthe inhibitor.
- inhibition refers to reduction ofa disease or symptoms ofdisease.Thus, inhibition mayinclude, at least in part, partiallyor totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating,
- the term“activation”,“activate”,“activating”and the like in reference to a protein-activator (e.g.agonist)interaction means positivelyaffecting (e.g.
- activation mayinclude, at least in part, partiallyor totallyincreasing stimulation, increasing or enabling activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activityor the amount of a protein decreased in a disease.
- activation mayinclude, at least in part, partiallyor totally increasing stimulation, increasing or enabling activation, or activating, sensitizing, or up- regulating signal transduction or enzymatic activityor the amount ofa protein.
- modulator refers to a composition that increases or decreases the level ofa target molecule or the function ofa target molecule.
- a modulator is an anti- cancer agent.
- a modulator is an estrogen receptor antagonist.
- a modulator is a hormone receptor antagonist.
- a modulator is an estrogen receptor inhibitor.
- a modulator is an estrogen receptor covalent modifier.
- An“additional agent”or“further agent”, as used herein, refer to a compound for use in conjuction withthe compounds provided herein (the compunds ofFormula Iand embodiments thereof).
- An additional agent or further agent maybe an anti-cancer agent.
- the additional agent or further agent is an agent for treating a hyperproliferative disorder.
- the further agent is a chemotherapeutic.
- the further agent is an agent for treating breast cancer.
- the further agent is an agent for treating lung cancer.
- the further agent is an agent for treating a gynecological cancer.
- the further agent is an agent for treating ovarian cancer.
- the further agent is an agent for treating endometrial cancer.
- the further agent is an agent for treating prostate cancer.
- the further agent is an agent for treating lymphangioleiomyomatosis.
- the further agent is an agent for inhibiting estrogen receptor activity.
- the additional agent or further agent is an agent for treating a hyperproliferative disorder.
- the further agent is an aromatase inhibitor.
- the further agent is a HER-2 inhibitor.
- the further agent is Herceptin.
- the further agent is fulvestrant, clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene, ospemifene, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, aminoglutethimide, or testolactone.
- the further agent is tamoxifen.
- the further agent is an EGFR inhibitor (e.g.gefitinib (IressaTM), erlotinib (Tarceva TM), cetuximab (ErbituxTM), lapatinib (TYKERBTM), panitumumab (VECTIBIXTM), vandet
- EGFR inhibitor e.g.gefit
- the further agent is a mammalian target ofrapamycin (mTOR) inhibitor (suchas everolimus)for use in treating cancer (e.g.in breast and NSCLC tumors); HER2-targeted therapeutics (suchas trastuzumab, lapatinib, trastuzumab- emtansine)for use in treating cancer (e.g.ER-positive breast cancers withoverexpression ofHER-2 receptors);HER3- targeted agents (e.g.pertuzumab);EGFR-targeted therapeutics (suchas erlotinib, gefitinib, afitinib)for treating cancer (e.g.NSCLC expressing mutant EGFR or having EGFR-positivity); tamoxifen or aromatase inhibitors
- mTOR mammalian target ofrapamycin
- HER2-targeted therapeutics suchas trastuzumab, lapatinib, trastuzumab- emtansine
- Anti-cancer agent or“anti-cancer drug” is used in accordance withits plain ordinary meaning and refers to a composition (e.g.compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the abilityto inhibit the growthor proliferation ofcells.
- an anti-cancer agent is a chemotherapeutic.
- an anti- cancer agent is an agent approved bythe FDA or similar regulatoryagencyofa countryother than the USA, for treating cancer.
- anti-androgens e.g., Casodex, Flutamide, MDV3100, or ARN-509
- MEK e.g.MEK1, MEK2, or MEK1 and MEK2
- Inhibitors e.g.XL518, CI-1040, PD035901, selumetinib/ AZD6244, GSK1120212/ trametinib, GDC-0973, AR
- cyclophosphamide ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine,
- cyclophosphamide chlorambucil, meiphalan
- ethylenimine and methylmelamines e.g., hexamethlymelamine, thiotepa
- alkyl sulfonates e.g., busulfan
- nitrosoureas e.g., carmustine, lomusitne, semustine, streptozocin
- triazenes decarbazine
- anti-metabolites e.g.,5- azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxouridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant
- fluorodaunorunicin hydrochloride gadolinium texaphyrin;gallium nitrate;gelatinase inhibitors; gemcitabine;glutathione inhibitors;hepsulfam;immunostimulant peptides;insulin-like growth factor-1 receptor inhibitor;interferon agonists;interferons;interleukins;letrozole;leukemia inhibiting factor;leukocyte alpha interferon;leuprolide+estrogen+progesterone;leuprorelin; matrilysin inhibitors;matrixmetalloproteinase inhibitors;MIFinhibitor;mifepristone;
- mismatched double stranded RNA mismatched double stranded RNA;monoclonal antibody,;mycobacterial cell wall extract;nitric oxide modulators;oxaliplatin;panomifene;pentrozole;phosphatase inhibitors;plasminogen activator inhibitor;platinum complex;platinum compounds;prednisone;proteasome inhibitors; protein A-based immune modulator;protein kinase C inhibitor;protein tyrosine phosphatase inhibitors;purine nucleoside phosphorylase inhibitors;ras farnesyl protein transferase inhibitors; ras inhibitors;ras-GAP inhibitor;ribozymes;signal transduction inhibitors;signal transduction modulators;single chain antigen-binding protein;stem cell inhibitor;stem-cell division inhibitors;stromelysin inhibitors;synthetic glycosaminoglycans;tamoxifen methiodide;
- telomerase inhibitors e.g., thyroid stimulating hormone;translation inhibitors;tyrosine kinase inhibitors;urokinase receptor antagonists;steroids (e.g.,dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH)suchas goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethlystilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate,
- GnRH gonadotropin-releasing hormone agonists
- progestins e.g., hydroxypro
- fluoxymesterone antiandrogen (e.g., flutamide), immunostimulants (e.g.,Bacillus Calmette- Guérin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGFmonoclonal antibodies), immunotoxins (e.g.,anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy(e.g.,anti- CD20 monoclonal antibodyconjugated to 111 In, 90 Y, or 131 I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastat
- duocarmycin analogs duocarmycin analogs, enediynes (suchas neocarzinostatin and calicheamicins), leptomycin derivatives, maytansinoids and maytansinoid analogs (e.g.mertansine), methotrexate, mitomycin C, taxoids, vinca alkaloids (suchas vinblastine and vincristine), epothilones (e.g.epothilone B), fluvestrant, camptothecin and its clinical analogs topotecan and irinotecan, SERMS (e.g., clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene,
- SERMS e.g., clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremif
- “Chemotherapeutic”or“chemotherapeutic agent” is used in accordance withits plain ordinary meaning and refers to a chemical composition or compound having antineoplastic properties or the abilityto inhibit the growthor proliferation ofcells.
- “Patient”or“subject in need thereof”or“subject” refers to a living organism suffering from or prone to a disease or condition that can be treated byadministration ofa compound or pharmaceutical composition or bya method, as provided herein.Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals.In some embodiments, a patient is human. In some embodiments, a subject is human. [0093] “Disease”or“condition”refer to a state ofbeing or healthstatus ofa patient or subject capable ofbeing treated witha compound, pharmaceutical composition, or method provided herein.In some embodiments, the disease is a disease having the symptom ofcell
- the disease is a disease having the symptom ofan aberrant level ofestrogen receptor activity.
- the disease is a cancer.
- “cancer” refers to human cancers and carcinomas, sarcomas,
- adenocarcinomas, lymphomas, leukemias, etc. including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, pancreas, stomach, brain, head and neck, skin, uterine, testicular, glioma, esophagus, and liver cancer, including hepatocarcinoma, lymphoma, including B-acute lymphoblastic lymphoma, non-Hodgkin’s lymphomas (e.g., Burkitt’s, Small Cell, and Large Cell lymphomas), Hodgkin’s lymphoma, leukemia (including AML, ALL, and CML), or multiple myeloma.
- the disease is breast cancer.
- the disease is hormone sensitive breast cancer.
- the disease is hormone refractory (insensitive)breast cancer.
- the disease is ER positive breast cancer.
- the disease is ER negative breast cancer.
- Exemplarycancers that maybe treated with a compound or method provided herein include cancer ofthe prostate, thyroid, endocrine system, brain, breast, cervix, colon, head & neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, Medulloblastoma, colorectal cancer, pancreatic cancer.
- Additional examples mayinclude, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primarythrombocytosis, primary macroglobulinemia, primarybrain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinarybladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblasto
- leukemia refers broadlyto progressive, malignant diseases ofthe blood- forming organs and is generallycharacterized bya distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow.Leukemia is generallyclinically classified on the basis of(1)the duration and character ofthe disease-acute or chronic;(2)the type ofcell involved;myeloid (myelogenous), lymphoid (lymphogenous), or monocytic;and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic).
- Exemplaryleukemias that maybe treated witha compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic le
- hemocytoblastic leukemia histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia,
- sarcoma generally refers to a tumor whichis made up of a substance like the embryonic connective tissue and is generallycomposed ofcloselypacked cells embedded in a fibrillar or homogeneous substance.
- Sarcomas that maybe treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal
- melanoma is taken to mean a tumor arising from the melanocytic system of the skin and other organs.
- Melanomas that maybe treated witha compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passeymelanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.
- carcinoma refers to a malignant new growthmade up ofepithelial cells tending to infiltrate the surrounding tissues and give rise to metastases.
- Exemplarycarcinomas that maybe treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullarythyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma,
- signaling pathway refers to a series ofinteractions between cellular and optionallyextra-cellular components (e.g.proteins, nucleic acids, small molecules, ions, lipids)that conveys a change in one component to one or more other components, whichin turn mayconveya change to additional components, whichis optionallypropagated to other signaling pathwaycomponents.
- optionallyextra-cellular components e.g.proteins, nucleic acids, small molecules, ions, lipids
- aberrant refers to different from normal.W hen used to describe enzymatic activity, aberrant refers to activitythat is greater or less than a normal control or the average ofnormal non-diseased control samples.Aberrant activitymayrefer to an amount ofactivitythat results in a disease, wherein returning the aberrant activityto a normal or non- disease-associated amount (e.g.byadministering a compound or using a method as described herein), results in reduction ofthe disease or one or more disease symptoms.
- nucleic acid or“oligonucleotide”or“polynucleotide”or grammatical equivalents used herein means at least two nucleotides covalentlylinked together.
- Oligonucleotides are typicallyfrom about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50 or more nucleotides in length, up to about 100 nucleotides in length.
- Nucleic acids and polynucleotides are a polymers ofanylength, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc.
- Nucleic acids containing one or more carbocyclic sugars are also included within one definition ofnucleic acids.
- a particular nucleic acid sequence also encompasses“splice variants.”
- a particular protein encoded bya nucleic acid encompasses anyprotein encoded bya splice variant ofthat nucleic acid.“Splice variants,”as the name suggests, are products ofalternative splicing ofa gene.After transcription, an initial nucleic acid transcript maybe spliced suchthat different (alternate)nucleic acid splice products encode different polypeptides.
- Mechanisms for the production ofsplice variants vary, but include alternate splicing ofexons.Alternate polypeptides derived from the same nucleic acid byread-throughtranscription are also encompassed bythis definition.Anyproducts ofa splicing reaction, including recombinant forms ofthe splice products, are included in this definition.
- a nucleic acid is“operablylinked”when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretoryleader is operablylinked to DNA for a polypeptide ifit is expressed as a preprotein that participates in the secretion ofthe polypeptide;
- a promoter or enhancer is operablylinked to a coding sequence ifit affects the transcription ofthe sequence; or
- a ribosome binding site is operablylinked to a coding sequence ifit is positioned so as to facilitate translation.
- “operablylinked” means that the DNA sequences being linked are near eachother, and, in the case ofa secretoryleader, contiguous and in reading phase.However, enhancers do not have to be contiguous.Linking is accomplished byligation at convenient restriction sites.Ifsuchsites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance withconventional practice.
- nucleic acids or polypeptide sequences refer to two or more sequences or subsequences that are the same or have a specified percentage ofamino acid residues or nucleotides that are the same (i.e., about 60% identity, preferably61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% ,94%, 95%, 96%, 97%, 98%, 99% or higher identityover a specified region when compared and aligned for maximum correspondence over a comparison window or designated region)as measured using a BLASTor BLAST2.0 sequence comparison algorithms withdefault parameters described below, or byman
- identity forms over a region that is at least about 10 amino acids or 20 nucleotides in length, or more preferablyover a region that is 10-50 amino acids or 20-50 nucleotides in length.
- percent (%)amino acid sequence identity is defined as the percentage ofamino acids in a candidate sequence that are identical to the amino acids in a reference sequence, after aligning the sequences and introducing gaps, ifnecessary, to achieve the maximum percent sequence identity.Alignment for purposes ofdetermining percent sequence identitycan be achieved in various ways that are within the skill in the art, for instance, using publiclyavailable computer software suchas BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software.Appropriate parameters for measuring alignment, including anyalgorithms needed to achieve maximal alignment over the full-lengthofthe sequences being compared can be determined byknown methods.
- sequence comparisons typicallyone sequence acts as a reference sequence, to whichtest sequences are compared.W hen using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.Preferably, default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
- A“comparison window”, as used herein, includes reference to a segment ofanyone of the number ofcontiguous positions selected from the group consisting offrom 10 to 600, usually about 50 to about 200, more usuallyabout 100 to about 150 in which a sequence maybe compared to a reference sequence ofthe same number ofcontiguous positions after the two sequences are optimallyaligned.
- Methods ofalignment ofsequences for comparison are well- known in the art.
- Optimal alignment ofsequences for comparison can be conducted, e.g., bythe local homologyalgorithm ofSmith& W aterman, Adv.Appl.Math.2:482 (1981), bythe homologyalignment algorithm ofNeedleman & W unsch, J.Mol.Biol.48:443 (1970), bythe searchfor similaritymethod ofPearson & Lipman, Proc.Nat’l.Acad.Sci.USA 85:2444 (1988), bycomputerized implementations
- phrase“selectively(or specifically)hybridizes to” refers to the binding, duplexing, or hybridizing of a molecule onlyto a particular nucleotide sequence witha higher affinity, e.g., under more stringent conditions, than to other nucleotide sequences (e.g., total cellular or library DNA or RNA).
- stringent hybridization conditions refers to conditions under whicha probe will hybridize to its target subsequence, typicallyin a complexmixture ofnucleic acids, but to no other sequences.Stringent conditions are sequence-dependent and will be different in different circumstances.Longer sequences hybridize specificallyat higher temperatures.An extensive guide to the hybridization ofnucleic acids is found in Tijssen, Techniques in
- stringent conditions are selected to be about 5-10°C lower than the thermal melting point (T m )for the specific sequence at a defined ionic strengthpH.
- T m is the temperature (under defined ionic strength, pH, and nucleic concentration)at which50% ofthe probes complementaryto the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at T m , 50% ofthe probes are occupied at equilibrium).
- Stringent conditions may also be achieved withthe addition ofdestabilizing agents suchas formamide.
- a positive signal is at least two times background, preferably10 times background hybridization.
- Exemplarystringent hybridization conditions can be as following: 50% formamide, 5xSSC, and 1% SDS, incubating at 42°C, or, 5xSSC, 1%
- nucleic acids that do not hybridize to eachother under stringent conditions are still substantiallyidentical if the polypeptides whichtheyencode are substantiallyidentical.This occurs, for example, when a copyofa nucleic acid is created using the maximum codon degeneracypermitted bythe genetic code.In suchcases, the nucleic acids typicallyhybridize under moderatelystringent hybridization conditions.
- Exemplary moderatelystringent hybridization conditions” include a hybridization in a buffer of40% formamide, 1 M NaCl, 1% SDS at 37°C, and a washin 1X SSC at 45°C.A positive hybridization is at least twice background.
- substitution ofone amino acid residue for another within the same class or group is referred to herein as a“conservative”substitution.
- Conservative amino acid substitutions can frequentlybe made in a protein without significantlyaltering the conformation or function ofthe protein.
- substitution ofone amino acid residue for another from a different class or group is referred to herein as a“non-conservative”substitution.
- non-conservative amino acid substitutions tend to modifyconformation and function ofa protein.
- the conservative amino acid substitution comprises substituting anyofglycine (G), alanine (A), isoleucine (I), valine (V), and leucine (L)for anyother ofthese aliphatic amino acids;serine (S)for threonine (T)and vice versa;aspartic acid (D)for glutamic acid (E)and vice versa;glutamine (Q)for asparagine (N)and vice versa;lysine (K)for arginine (R)and vice versa;phenylalanine (F), tyrosine (Y)and tryptophan (W )for anyother ofthese aromatic amino acids;and methionine (M)for cysteine (C)and vice versa.Other substitutions can also be considered conservative, depending on the environment ofthe particular amino acid and its role in the three- dimensional structure ofthe protein.For example, glycine (G), glycine (G), isoleucine (I), valine (V), and le
- Polypeptide,”“peptide,”and“protein” are used herein interchangeablyand mean any peptide-linked chain ofamino acids, regardless oflengthor post-translational modification.As noted below, the polypeptides described herein can be, e.g., wild-type proteins, biologically- active fragments ofthe wild-type proteins, or variants ofthe wild- type proteins or fragments.
- Variants in accordance withthe disclosure, can contain amino acid substitutions, deletions, or insertions. The substitutions can be conservative or non-conservative.
- the proteins can be isolated.
- the term“purified”or“isolated”as applied to anyofthe proteins described herein refers to a polypeptide that has been separated or purified from components (e.g., proteins or other naturally-occurring biological or organic molecules)whichnaturallyaccompanyit, e.g., other proteins, lipids, and nucleic acid in a cell expressing the proteins.
- a polypeptide is purified when it constitutes at least 60 (e.g., at least 65, 70, 75, 80, 85, 90, 92, 95, 97, or 99)%, byweight, ofthe total protein in a sample.
- an amino acid residue in a protein "corresponds" to a given residue when it occupies the same essential structural position within the protein as the given residue.
- a selected residue in a selected protein corresponds to Cys784 ofhuman androgen receptor when the selected residue occupies the same essential spatial or other structural relationship as Cys 784 in human androgen receptor.
- the position in the aligned selected protein aligning withCys784 is said to correspond to Cys784.
- a three dimensional structural alignment can also be used, e.g., where the structure ofthe selected protein is aligned for maximum correspondence withthe human androgen receptor protein and the overall structures compared.
- an amino acid that occupies the same essential position as Cys784 in the structural model is said to correspond to the Cys784 residue.
- “Pharmaceuticallyacceptable excipient”and“pharmaceuticallyacceptable carrier” refer to a substance that aids the administration ofan active agent to and absorption bya subject and can be included in a compositions disclosed herein without causing a significant adverse toxicological effect on the patient.
- pharmaceuticallyacceptable excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (suchas Ringer's solution), alcohols, oils, gelatins, carbohydrates suchas lactose, amylose or starch, fattyacid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like.Suchpreparations can be sterilized and, ifdesired, mixed withauxiliaryagents such as lubricants, preservatives, stabilizers, wetting agents, and the like.
- preparation is intended to include the formulation ofthe active compound withencapsulating material as a carrier providing a capsule in whichthe active component with or without other carriers, is surrounded by a carrier, whichis thus in association withit.
- administering means oral administration, administration as a suppository, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intralesional, intrathecal, intracranial, intranasal or subcutaneous administration, or the implantation ofa slow- release device, e.g.,a mini-osmotic pump, to a subject.
- administering is byanyroute, including parenteral and transmucosal (e.g.,buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
- Parenteral and transmucosal e.g.,buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal.
- Parenteral and transmucosal e.g.,buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal.
- Parenteral and transmucosal e.g
- the compound ofthe invention can be administered alone or can be coadministered to the patient.Coadministration is meant to include simultaneous or sequential administration ofthe compound individuallyor in combination (more than one compound or agent).Thus, the preparations can also be combined, when desired, withother active substances (e.g.to reduce metabolic degradation, to increase degradation ofa prodrug and release ofthe drug, detectable agent).
- the compositions ofthe present invention can be delivered bytransdermally, bya topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
- Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion bythe patient.Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible
- compositions ofthe present invention can also be delivered as microspheres for slow release in the body.
- microspheres can be administered via intradermal injection ofdrug-containing microspheres, whichslowlyrelease subcutaneously(see Rao, J.
- the formulations ofthe compositions ofthe present invention can be delivered bythe use ofliposomes whichfuse with the cellular membrane or are endocytosed, i.e.,byemploying receptor ligands attached to the liposome, that bind to surface membrane protein receptors ofthe cell resulting in endocytosis.
- compositions ofthe present invention can focus the delivery ofthe compositions ofthe present invention into the target cells in vivo.
- the compositions ofthe present invention can also be delivered as nanoparticles.
- compositions provided bythe present invention include compositions wherein the active ingredient (e.g.compounds described herein, including embodiments or examples)is contained in a therapeuticallyeffective amount, i.e., in an amount effective to achieve its intended purpose.
- a therapeuticallyeffective amount i.e., in an amount effective to achieve its intended purpose.
- the actual amount effective for a particular application will depend, inter alia,on the condition being treated.W hen administered in methods to treat a disease, suchcompositions will contain an amount ofactive ingredient effective to achieve the desired result, e.g., reducing, eliminating, or slowing the progression ofdisease symptoms (e.g.
- the dosage and frequency(single or multiple doses)administered to a mammal can varydepending upon a varietyoffactors, for example, whether the mammal suffers from another disease, and its route ofadministration;size, age, sex, health, bodyweight, bodymass index, and diet ofthe recipient;nature and extent ofsymptoms ofthe disease being treated (e.g.symptoms ofcancer), kind ofconcurrent treatment, complications from the disease being treated or other health-related problems.Other therapeutic regimens or agents can be used in conjunction with the methods and compounds ofApplicants'invention.Adjustment and manipulation of established dosages (e.g., frequencyand duration)are well within the abilityofthose skilled in the art.
- the therapeuticallyeffective amount can be initiallydetermined from cell culture assays.Target concentrations will be those concentrations ofactive compound(s)that are capable ofachieving the methods described herein, as measured using the methods described herein or known in the art.
- therapeuticallyeffective amounts for use in humans can also be determined from animal models.
- a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals.
- the dosage in humans can be adjusted bymonitoring compounds effectiveness and adjusting the dosage upwards or downwards, as described above.Adjusting the dose to achieve maximal efficacyin humans based on the methods described above and other methods is well within the capabilities ofthe ordinarilyskilled artisan.
- Dosages maybe varied depending upon the requirements ofthe patient and the compound being employed. The dose administered to a patient, in the context ofthe present invention should be sufficient to effect a beneficial therapeutic response in the patient over time.
- the size ofthe dose also will be determined bythe existence, nature, and extent ofanyadverse side-effects.Determination ofthe proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated withsmaller dosages whichare less than the optimum dose ofthe compound.Thereafter, the dosage is increased bysmall increments until the optimum effect under circumstances is reached. [0123] Dosage amounts and intervals can be adjusted individuallyto provide levels ofthe administered compound effective for the particular clinical indication being treated.This will provide a therapeutic regimen that is commensurate withthe severityofthe individual's disease state.
- an effective prophylactic or therapeutic treatment regimen can be planned that does not cause substantial toxicityand yet is effective to treat the clinical symptoms demonstrated bythe particular patient. This planning should involve the careful choice ofactive compound byconsidering factors suchas compound potency, relative bioavailability, patient bodyweight, presence and severityofadverse side effects, preferred mode ofadministration and the toxicityprofile ofthe selected agent.
- the compounds described herein can be used in combination withone another, with other active agents known to be useful in treating cancer, or withadjunctive agents that maynot be effective alone, but maycontribute to the efficacyofthe active agent.
- co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours ofa second active agent.Co-administration includes administering two active agents simultaneously, approximatelysimultaneously(e.g., within about 1, 5, 10, 15, 20, or 30 minutes ofeachother), or sequentiallyin anyorder. In some embodiments, co-administration can be accomplished byco-formulation, i.e., preparing a single pharmaceutical composition including bothactive agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents maybe linked or conjugated to one another. In some embodiments, the compounds described herein maybe combined withtreatments for cancer suchas radiation or surgery.
- A“drug-resistant estrogen receptor” is a modified (relative to wildtype)estrogen receptor that is inhibited less effectivelybythe drug than a wildtype estrogen receptor.
- A“drug- resistant human estrogen receptor” is a modified (relative to wildtype)human estrogen receptor that is inhibited less effectivelybythe drug than a wildtype human estrogen receptor.
- A“drug-resistant cancer” is a cancer that is inhibited less effectivelybythe drug than a non-drug resistant cancer.
- An“antiestrogen-resistant cancer” is a cancer that is inhibited less effectivelybythe antiestrogen than a non-antiestrogren resistant cancer.
- An“endocrine therapeutic-resistant cancer” is a cancer that is inhibited less effectivelybythe endocrine therapeutic than a non-endocrine therapeutic resistant cancer.
- antiestrogen refers to a compound that binds estrogen receptor without one or more ofthe estrogen receptor activities associated withthe binding ofestrogen to the estrogen receptor.
- an antiestrogen is a compound that inhibits one or more effects of estrogen (e.g., on ER, on a cell, on a tissue, or on an organism).
- an antiestrogen include fluvestrant, clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene, and ospemifene.
- the term“endocrine therapeutic” refers to a compound that is effective for modulating hormone activityin a subject.Use ofan endocrine therapeutic in treatment ofa subject is “endocrine therapy”.Modulation ofhormone activitybyan endocrine therapeutic mayinclude increasing, decreasing, blocking, removing, or otherwise changing the level ofa hormone or the level ofactivityofa hormone.
- Endocrine therapeutics include antiestrogens, aromatase inhibitors, SERMs, fluvestrant, clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene, ospemifene, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, aminoglutethimide, and testolactone.
- estrogen receptor or“ER” refers to an established member ofthe nuclear receptor familyofreceptors whichis a transcription factor activated bybinding ligands suchas the hormones 17 ⁇ -estradiol, estriol, estrone, etc.
- “estrogen receptor” or“ER” refers to a nuclear receptor whichis a transcription factor activated bybinding ligands suchas the hormones 17 ⁇ -estradiol, estriol, and/or estrone.
- “estrogen receptor” or“ER” refers to a nuclear receptor which is a transcription factor activated by binding the hormone 17 ⁇ - estradiol.
- the term“estrogen receptor” mayrefer to the nucleotide sequence or protein sequence ofhuman estrogen receptor.
- the term“estrogen receptor” mayrefer to the nucleotide sequence or protein sequence of human estrogen receptor 1 (a.k.a.
- ER-alpha, ERalpha, or ER ⁇ e.g., Entrez2099, Uniprot P03372, RefSeqNM_000125, OMIM 133430, NP_000116, NP_000116.2, NM_000125.3, GI:62821794, and/or GI: 170295798).
- the term“estrogen receptor” mayrefer to the nucleotide sequence or protein sequence ofhuman estrogen receptor 2 (a.k.a.ER-beta, ERbeta, or ER ⁇ ) (e.g., Entrez 2100, Uniprot Q92731, RefSeq NM_001040275, OMIM 601663, and/or GI: 94538324).
- “estrogen receptor” is wild-type estrogen receptor.
- “estrogen receptor” is wild-
- an estrogen receptor is the wildtype human ER ⁇ . In embodiments, an estrogen receptor is the wildtype human ER ⁇ or ER ⁇ . In embodiments, an estrogen receptor is the wildtype human ER ⁇ and ER ⁇ . In embodiments, the estrogen receptor is a mutant estrogen receptor.In embodiments, the mutant estrogen receptor is associated witha disease that is not associated withwildtype estrogen receptor (e.g., drug resistant cancer). In embodiments, the estrogen receptor includes at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations)compared to the sequence above.
- the estrogen receptor includes at least one amino acid mutation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mutations)compared to the sequence above.
- dose refers, in the usual and customarysense, to the amount ofactive ingredient given to an individual at eachadministration.
- the dose maygenerallyrefer to the amount ofdisease treatment.
- a dosage form refers to the particular format ofthe composition, active compound, pharmaceutical or pharmaceutical composition, and depends on the route ofadministration.
- a dosage form can be in a liquid form for nebulization, e.g., for inhalants, in a tablet or liquid, e.g., for oral delivery, or a saline solution, e.g., for injection.
- a composition can contain a pluralityofactive ingredients (e.g., two active ingredients)in a pluralityofseparate dosage forms (e.g., a separate dosage form for eachoftwo active ingredients).
- a composition can contain a single dosage form (e.g., a single pill, tablet injection
- CDK4 inhibitor and the like refer, in the usual and customarysense, to a compound whichinhibits the function ofCDK4.
- the term“CDK4” refer, in the usual and customarysense, to cyclin-dependent kinase 4, as well known in the art.
- the term“CDK6 inhibitor”and the like refer, in the usual and customarysense, to a compound whichinhibits the function ofCDK6.
- CDK6 refer, in the usual and customarysense, to cyclin- dependent kinase 6, as well known in the art.
- the terms“CDK 4/6 inhibitor”and the like refer, in the usual and customarysense, to a compound whichinhibits the function ofeither CDK4 or CDK6, or bothCDK4 and CDK6.
- ExemplaryCDK 4/6 inhibitors include palbociclib (PD- 0332991), ribociclib (LEE011)and abemaciclib (LY2835219), se
- synergy refers to a measured effect ofcompounds administered in combination where the measured effect is greater than the sum ofthe individual effects ofeachofthe compounds administered alone as a single agent.
- a “combined synergistic amount” as used herein refers to the sum of a first amount (e.g., an amount ofa compound described herein)and a second amount (e.g., an amount ofa CDK4 inhibitor or a CDK6 inhibitor)that results in a synergistic effect (i.e.an effect greater than an additive effect).
- compositions whichincludes a further agent or additional agent as defined herein, suchas a CDK4 inhibitor or a CDK6 inhibitor, and a compound, or a pharmaceuticall acceptable salt thereof, havin the formula
- R 1 is independentlya hydrogen, halogen, -NR 2 R 3 , -CX a
- R 2 is independentlya hydrogen, halogen, -CX b
- R 3 is independentlya hydrogen, halogen, -CX c
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independentlyhydrogen,
- the composition is provided as a single dosage form including both a CDK 4 inhibitor or a CDK 6 inhibitor in combination with a compound ofFormula (I).
- the composition is provided as a pluralityofdosage forms, eachdosage form including a CDK 4 inhibitor or a CDK 6 inhibitor, and a compound ofFormula (I).
- the compound has the structure offormula (I):
- R 1 is independentlya hydrogen
- R 2 is independentlya hydrogen, halogen,
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents may optionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- L is independentlya bond, -NR 4 -, -NR 4 C(O)-, -C(O)NR 4 -, -O-, -S-,– C(O)-, -S(O)-,
- R 4 is independentlya hydrogen, halogen, -CX d
- n1, n2, n3, and n4 are independentlyan integer from 0 to 4.
- the symbols X, X a , X b , X c and X d are independently–Cl, -Br, -I, or -F.
- the compound has the formula (I):
- R 1 is independentlya hydrogen
- R 2 is independentlya hydrogen
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- L is independentlya bond, -NR 4 -, -NR 4 C(O)-, -C(O)NR 4 -, -O-, -S-,–C(O)-, -S(O)-, -S(O) 2 -, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted substituted or unsubstituted
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independentlyhydrogen,
- n1, n2, n3, and n4 are independentlyan integer from 0 to 4.
- the symbols X, X a , X b , X c and X d are independently–Cl, -Br, -I, or -F. [0140]
- the compound has the formula (1a):
- the compound has the formula (II):
- the compound has the formula(IIa):
- the compound has the formula (IIb):
- R 1 is independentlyhalogen, -NR 2 R 3 , -CX a
- R 1 is independentlyhydrogen.In embodiments, R 1 is independently-NR 2 R 3 .In embodiments, R 1 is independently–NH 2 .In embodiments, R 1 is independently-CF 3 .In embodiments, R 1 is independently-CCl 3 .In embodiments, R 1 is independently-N(O) 2 .In embodiments, R 1 is independentlyhalogen.In embodiments, R 1 is independently-F.In embodiments, R 1 is independently-Cl.In embodiments, R 1 is independently-Br.In embodiments, R 1 is independently-I.In embodiments, R 1 is independentlysubstituted or unsubstituted cycloalkyl, substituted
- R 1 is independentlysubstituted or unsubstituted C 3 -C 8 cycloalkyl. In embodiments, R 1 is independentlyunsubstituted C 3 -C 8 cycloalkyl. In embodiments, R 1 is independentlysubstituted or unsubstituted C 3 -C 7 cycloalkyl. In embodiments, R 1 is
- R 1 is independentlyunsubstituted C 3 -C 7 cycloalkyl.
- R 1 is independentlysubstituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 1 is independently unsubstituted 3 to 8 membered heterocycloalkyl.
- R 1 is independently substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 1 is independentlyunsubstituted 3 to 7 membered heterocycloalkyl.
- R 1 is independentlysubstituted or unsubstituted C 6 -C 12 aryl.
- R 1 is independently unsubstituted C 6 -C 12 aryl.
- R 1 is independentlysubstituted or unsubstituted C 6 - C 10 aryl.
- R 1 is independentlyunsubstituted C 6 -C 10 aryl.
- R 1 is independentlysubstituted C 6 -C 10 aryl.
- R 1 is independentlydimethylaminoethyl. In embodiments, R 1 is independentlydimethylaminopropyl. In embodiments, R 1 is independentlyethylmorpholinyl. In embodiments, R 1 is independentlymorpholinyl. [0148] In embodiments, R 2 is independentlyhalogen, -CX b
- R 2 is independentlyhydrogen. In embodiments, R 2 is independentlyhalogen. In embodiments, R 2 is independentlysubstituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- R 2 is independentlysubstituted or unsubstituted C 1 -C 12 alkyl. In embodiments, R 2 is independentlyunsubstituted C 1 -C 12 alkyl. In embodiments, R 2 is
- R 2 independentlysubstituted or unsubstituted C 1 -C 8 alkyl.
- R 2 is independently unsubstituted C 1 -C 8 alkyl.
- R 2 is independentlysubstituted or unsubstituted C 1 - C 4 alkyl.
- R 2 is independentlyunsubstituted C 1 -C 4 alkyl.
- R 2 is independentlyunsubstituted methyl.
- R 2 is independentlyunsubstituted ethyl.
- R 2 is independentlyunsubstituted propyl. In embodiments, R 2 is independently substituted or unsubstituted 2 to 12 membered heteroalkyl. In embodiments, R 2 is independently unsubstituted 2 to 12 membered heteroalkyl.In embodiments, R 2 is independentlysubstituted or unsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 2 is independentlyunsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 2 is independentlysubstituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 2 is independentlyunsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 2 is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.In embodiments, R 2 is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substitute
- R 3 is independentlyhydrogen. In embodiments, R 3 is independentlyhalogen. In embodiments, R 3 is independentlysubstituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- R 3 is independentlysubstituted or unsubstituted C 1 -C 12 alkyl. In embodiments, R 3 is independentlyunsubstituted C 1 -C 12 alkyl. In embodiments, R 3 is
- R 3 independentlysubstituted or unsubstituted C 1 -C 8 alkyl.
- R 3 is independently unsubstituted C 1 -C 8 alkyl.
- R 3 is independentlysubstituted or unsubstituted C 1 - C 4 alkyl.
- R 3 is independentlyunsubstituted C 1 -C 4 alkyl.
- R 3 is independentlyunsubstituted methyl.
- R 3 is independentlyunsubstituted ethyl.
- R 3 is independentlyunsubstituted propyl. In embodiments, R 3 is independently substituted or unsubstituted 2 to 12 membered heteroalkyl. In embodiments, R 3 is independently unsubstituted 2 to 12 membered heteroalkyl.In embodiments, R 3 is independentlysubstituted or unsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 3 is independentlyunsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 3 is independentlysubstituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 3 is independentlyunsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 3 is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.In embodiments, R 3 is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substitute
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 2 and R 3 substituents are joined to form a substituted or unsubstituted heterocycloalkyl.
- R 2 and R 3 substituents are joined to form an unsubstituted heterocycloalkyl.
- R 2 and R 3 substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 2 and R 3 substituents are joined to form an unsubstituted 3 to 8 membered heterocycloalkyl.
- R 2 and R 3 substituents are joined to form a substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 2 and R 3 substituents are joined to form an unsubsti
- R 2 and R 3 substituents are joined to form a substituted or unsubstituted heteroaryl. In embodiments, R 2 and R 3 substituents are joined to form an unsubstituted heteroaryl. In embodiments, R 2 and R 3 substituents are joined to form a substituted or unsubstituted 5 to 10 membered heteroaryl.In embodiments, R 2 and R 3 substituents are joined to form an unsubstituted 5 to 10 membered heteroaryl.In embodiments, R 2 and R 3 substituents are joined to form a substituted or unsubstituted 5 to 9 membered heteroaryl. In embodiments, R 2 and R 3 substituents are joined to form an unsubstituted 5 to 9 membered heteroaryl. In embodiments, R 2 and R 3 substituents are joined to form a substituted or unsubstituted 5 to 6 membered heteroaryl.In embodiments, R 2 and R 3 substituents are joined to form
- Lis independentlya bond, -NR 4 -, -NR 4 C(O)-, -C(O)NR 4 -, -O-, -S-, –C(O)-, -S(O)-, -S(O) 2 -, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
- Lis independentlya bond.
- Lis Lis
- Lis independentlysubstituted or unsubstituted C 1 -C 12 alkylene In embodiments, Lis independentlyunsubstituted C 1 -C 12 alkylene.In embodiments, Lis independentlysubstituted or unsubstituted C 1 -C 8 alkylene.In embodiments, Lis independently unsubstituted C 1 -C 8 alkylene.In embodiments, Lis independentlysubstituted or unsubstituted C 1 -C 6 alkylene.In embodiments, Lis independentlyunsubstituted C 1 -C 6 alkylene.In embodiments, Lis independentlysubstituted or unsubstituted C 1 -C 4 alkylene.In embodiments, L is independentlyunsubstituted C 1 -C 4 alkylene.In embodiments, Lis independentlyunsubstituted methylene.In embodiments, Lis independentlyunsubstituted ethylene.In embodiments, Lis independentlyunsubstituted ethylene.In embodiment
- L is independentlysubstituted or unsubstituted 2 to 12 membered heteroalkylene.
- L is independentlyunsubstituted 2 to 12 membered heteroalkylene.
- L is independentlyunsubstituted 2 to 8 membered heteroalkylene.
- L is independentlyunsubstituted 2 to 6 membered heteroalkylene.
- L is independentlyunsubstituted 2 to 4 membered heteroalkylene.
- R 4 is independentlyhydrogen.
- R 4 is independentlysubstituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- R 4 is independentlysubstituted or unsubstituted C 1 -C 12 alkyl. In embodiments, R 4 is independentlyunsubstituted C 1 -C 12 alkyl. In embodiments, R 4 is
- R 4 independentlysubstituted or unsubstituted C 1 -C 8 alkyl.
- R 4 is independently unsubstituted C 1 -C 8 alkyl.
- R 4 is independentlysubstituted or unsubstituted C 1 - C 4 alkyl.
- R 4 is independentlyunsubstituted C 1 -C 4 alkyl.
- R 4 is independentlyunsubstituted methyl.
- R 4 is independentlyunsubstituted ethyl.
- R 4 is independentlyunsubstituted propyl. In embodiments, R 4 is independently substituted or unsubstituted 2 to 12 membered heteroalkyl.In embodiments, R 4 is independently unsubstituted 2 to 12 membered heteroalkyl.In embodiments, R 4 is independentlysubstituted or unsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 4 is independentlyunsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 4 is independentlysubstituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 4 is independentlyunsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 4 is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.In embodiments, R 4 is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substitute
- R 4 is independentlyunsubstituted C 3 -C 8 cycloalkyl. In embodiments, R 4 is independentlysubstituted or unsubstituted C 3 -C 7 cycloalkyl. In embodiments, R 4 is
- R 4 is independentlysubstituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R 4 is independentlyunsubstituted 3 to 8 membered heterocycloalkyl.In embodiments, R 4 is independentlysubstituted or unsubstituted 3 to 7 membered heterocycloalkyl.In embodiments, R 4 is independentlyunsubstituted 3 to 7 membered heterocycloalkyl. In embodiments, R 4 is independentlysubstituted or 3 to 7 membered heterocycloalkyl. In embodiments, R 4 is independentlysubstituted or unsubstituted C 6 -C 12 aryl. In embodiments, R 4 is independentlyunsubstituted C 6 -C 12 aryl. In embodiments, R4 is independentlysubstituted or unsubstituted C 6 -C 10 aryl.In embodiments, R 4 is independently unsubstituted C 6 -C 10 aryl.In embodiments
- R 5 is independentlyhydrogen.
- R 5 is independentlysubstituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
- R 5 is independently–NH 2 .
- R 5 is independently-CF 3 .
- R 5 is independently-CCl 3 .
- R 5 is independently-N(O) 2 .
- R 5 is independently-Br.In embodiments, R 5 is independently-I.In
- R 5 is independentlysubstituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. [0161] In embodiments, R 5 is independentlysubstituted or unsubstituted C 1 -C 12 alkyl. In embodiments, R 5 is independentlyunsubstituted C 1 -C 12 alkyl.In embodiments, R 5 is
- R 5 independentlysubstituted or unsubstituted C 1 -C 8 alkyl.
- R 5 is independently unsubstituted C 1 -C 8 alkyl.
- R 5 is independentlysubstituted or unsubstituted C 1 - C 4 alkyl.
- R 5 is independentlyunsubstituted C 1 -C 4 alkyl.
- R 5 is independentlyunsubstituted methyl.
- R 5 is independentlyunsubstituted ethyl.
- R 5 is independentlyunsubstituted propyl. In embodiments, R 5 is independently substituted or unsubstituted 2 to 12 membered heteroalkyl. In embodiments, R 5 is independently unsubstituted 2 to 12 membered heteroalkyl.In embodiments, R 5 is independentlysubstituted or unsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 5 is independentlyunsubstituted 2 to 8 membered heteroalkyl.In embodiments, R 5 is independentlysubstituted or unsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 5 is independentlyunsubstituted 2 to 4 membered heteroalkyl. In embodiments, R 5 is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.In embodiments, R 5 is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substitute
- R 5 is independentlyunsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl. In embodiments, R 5 is independentlysubstituted or unsubstituted C 3 -C 8 cycloalkyl. In embodiments, R 5 is
- R 5 is independentlyunsubstituted C 3 -C 8 cycloalkyl.
- R 5 is independentlysubstituted or unsubstituted C 3 -C 7 cycloalkyl.
- R 5 is independentlyunsubstituted C 3 -C 7 cycloalkyl.
- R 5 is independentlysubstituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 5 is independentlyunsubstituted 3 to 8 membered heterocycloalkyl.
- R 5 is independentlysubstituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 5 is independentlyunsubstituted 3 to 7 membered heterocycloalkyl.
- R 5 is independentlysubstituted or unsubstituted C 6 -C 12 aryl. In embodiments, R 5 is independentlyunsubstituted C 6 -C 12 aryl. In embodiments, R 5 is
- R 5 is independentlysubstituted or unsubstituted C 6 -C 10 aryl.
- R 5 is independently unsubstituted C 6 -C 10 aryl.
- R 5 is independentlysubstituted or unsubstituted 5 to 10 membered heteroaryl.
- R 5 is independentlyunsubstituted 5 to 10 membered heteroaryl.
- R 5 is independentlysubstituted or unsubstituted 5 to 9 membered heteroaryl.
- R 5 is independentlyunsubstituted 5 to 9 membered heteroaryl.
- R 5 is independently-CX e
- R 5 is
- R 5 is independently -CN.
- R 5 is independently-SO 2 Cl.
- R 5 is independently-SO n5 R 26 .
- R 5 is independently-SO v5 NR 23 R 24 .
- R 5 is independently -NHNH 2 .
- R 5 is independently -ONR 23 R 24 .
- R 5 is independently-OR 26 .
- R 5 is independently-NR 23 SO 2 R 26 .
- R 5 is independently- NR 23 C(O)-OR 25 .
- R 5 is independently-NR 23 OR 25 .
- R 5 is independently-OCX e
- R 5 is independentlya hydrogen, halogen, -CX e
- R 5 is independentlya hydrogen, -F, -CF 3 , or unsubstituted methyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted C 1 - C 4 alkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted C 1 -C 4 alkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted 2 to 12 membered heteroalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted 2 to 12 membered heteroalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substituted or unsubstituted 2 to 10 membered heteroalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted methyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted C 3 -C 8 cycloalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted 3 to 8 membered heterocycloalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independently substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted C 6 -C 12 aryl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independently unsubstituted C 6 -C 12 aryl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlysubstituted or unsubstituted 5 to 10 membered heteroaryl.
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , or R 26 is independentlyunsubstituted 5 to 10 membered heteroaryl.
- R 11 and R 12 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted heterocycloalkyl.
- R 11 and R 12 substituents are joined to form an unsubstituted heterocycloalkyl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 11 and R 12 substituents are joined to form an unsubstituted 3 to 8 membered heterocycloalkyl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 11 and R 12 substituents are joined to form an unsubsti
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 3 to 6 membered heterocycloalkyl. In embodiments, R 11 and R 12 substituents are joined to form an unsubstituted 3 to 6 membered heterocycloalkyl. [0172] In embodiments, R 11 and R 12 substituents are joined to form a substituted or
- R 11 and R 12 substituents are joined to form an unsubstituted heteroaryl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 5 to 10 membered heteroaryl.
- R 11 and R 12 substituents are joined to form an unsubstituted 5 to 10 membered heteroaryl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 5 to 9 membered heteroaryl.
- R 11 and R 12 substituents are joined to form an unsubstituted 5 to 9 membered heteroaryl.
- R 11 and R 12 substituents are joined to form a substituted or unsubstituted 5 to 6 membered heteroaryl.
- R 15 and R 16 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl. In embodiments, R 15 and R 16 substituents are joined to form a substituted or unsubstituted heterocycloalkyl.In embodiments, R 15 and R 16 substituents are joined to form an unsubstituted heterocycloalkyl. In embodiments, R 15 and R 16 substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R 15 and R 16 substituents are joined to form an unsubstituted 3 to 8 membered heterocycloalkyl. In embodiments, R 15 and R 16 substituents are joined to form a substituted or unsubstituted 3 to 7 membered heterocycloalkyl.In embodiments, R 15 and R 16 substituents are joined to form an unsubsti
- R 15 and R 16 substituents are joined to form a substituted or unsubstituted 3 to 6 membered heterocycloalkyl. In embodiments, R 15 and R 16 substituents are joined to form an unsubstituted 3 to 6 membered heterocycloalkyl. [0174] In embodiments, R 15 and R 16 substituents are joined to form a substituted or
- R 15 and R 16 substituents are joined to form an unsubstituted heteroaryl.
- R 15 and R 16 substituents are joined to form a substituted or unsubstituted 5 to 10 membered heteroaryl.
- R 15 and R 16 substituents are joined to form an unsubstituted 5 to 10 membered heteroaryl.
- R 15 and R 16 substituents are joined to form a substituted or unsubstituted 5 to 9 membered heteroaryl.
- R 15 and R 16 substituents are joined to form an unsubstituted 5 to 9 membered heteroaryl.
- R 15 and R 16 substituents are joined to form a substituted or unsubstituted 5 to 6 membered heteroaryl.
- R 19 and R 20 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted heterocycloalkyl.
- R 19 and R 20 substituents are joined to form an unsubstituted heterocycloalkyl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 19 and R 20 substituents are joined to form an unsubstituted 3 to 8 membered heterocycloalkyl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 19 and R 20 substituents are joined to form an unsubsti
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 3 to 6 membered heterocycloalkyl. In embodiments, R 19 and R 20 substituents are joined to form an unsubstituted 3 to 6 membered heterocycloalkyl. [0176] In embodiments, R 19 and R 20 substituents are joined to form a substituted or
- R 19 and R 20 substituents are joined to form an unsubstituted heteroaryl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 5 to 10 membered heteroaryl.
- R 19 and R 20 substituents are joined to form an unsubstituted 5 to 10 membered heteroaryl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 5 to 9 membered heteroaryl.
- R 19 and R 20 substituents are joined to form an unsubstituted 5 to 9 membered heteroaryl.
- R 19 and R 20 substituents are joined to form a substituted or unsubstituted 5 to 6 membered heteroaryl.
- R 23 and R 24 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 23 and R 24 substituents are joined to form a substituted or unsubstituted heterocycloalkyl.
- R 23 and R 24 substituents are joined to form an unsubstituted heterocycloalkyl.
- R 23 and R 24 substituents are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- R 23 and R 24 substituents are joined to form an unsubstituted 3 to 8 membered heterocycloalkyl.
- R 23 and R 24 substituents are joined to form a substituted or unsubstituted 3 to 7 membered heterocycloalkyl.
- R 23 and R 24 substituents are joined to form an unsubsti
- R 23 and R 24 substituents are joined to form a substituted or unsubstituted 3 to 6 membered heterocycloalkyl. In embodiments, R 23 and R 24 substituents are joined to form an unsubstituted 3 to 6 membered heterocycloalkyl. [0178] In embodiments, R 23 and R 24 substituents are joined to form a substituted or
- n is 0.In embodiments, n is 1.In embodiments, n is 2.In
- n is 3.In embodiments, n is 4.In embodiments, n is 5.In embodiments, m1 is 1. In embodiments, m1 is 2.In embodiments, m2 is 1.In embodiments, m2 is 2.In embodiments, m3 is 1.In embodiments, m3 is 2.In embodiments, m4 is 1.In embodiments, m4 is 2.In embodiments, m5 is 1.In embodiments, m5 is 2.In embodiments, v1 is 1.In embodiments, v1 is 2.In embodiments, v2 is 1.In embodiments, v2 is 2.In embodiments, v3 is 1.In
- v3 is 2.In embodiments, v4 is 1.In embodiments, v4 is 2.In embodiments, v5 is 1.In embodiments, v5 is 2.In embodiments, n1 is 0.In embodiments, n1 is 1.In embodiments, n1 is 1.In embodiments, v3 is 2.In embodiments, v4 is 1.In embodiments, v4 is 2.In embodiments, v5 is 1.In embodiments, v5 is 2.In embodiments, n1 is 0.In embodiments, n1 is 1.In
- n1 is 2.In embodiments, n1 is 3.In embodiments, n1 is 4.In embodiments, n2 is 0.In embodiments, n2 is 1.In embodiments, n2 is 2.In embodiments, n2 is 3.In
- n2 is 4.In embodiments, n3 is 0.In embodiments, n3 is 1.In embodiments, n3 is 2.In embodiments, n3 is 3.In embodiments, n3 is 4.In embodiments, n4 is 0.In
- n4 is 1.In embodiments, n4 is 2.In embodiments, n4 is 3.In embodiments, n4 is 4.In embodiments, n5 is 0.In embodiments, n5 is 1.In embodiments, n5 is 2.In
- n5 is 3.In embodiments, n5 is 4. [0180]
- X is independently–Cl.In embodiments, X is independently-Br.In embodiments, X is independently-I.In embodiments, X is independently-F.In embodiments, X a is independently–Cl.In embodiments, X a is independently-Br.In embodiments, X a is independently-I.In embodiments, X a is independently-F.In embodiments, X b is independently –Cl.In embodiments, X b is independently-Br.In embodiments, X b is independently-I.In embodiments, X b is independently-F.In embodiments, X c is independently–Cl.In
- X c is independently-Br.In embodiments, X c is independently-I.In
- X c is independently-F.
- X d is independently–Cl.In
- X d is independently-Br.In embodiments, X d is independently-I.In
- X d is independently-F.
- X e is independently–Cl.In
- X e is independently-Br.In embodiments, X e is independently-I.In
- X e is independently-F.
- R 1 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
- R 27 -substituted or unsubstituted aryl e.g.C 6 -C 10 aryl or C 6 aryl
- R 27 -substituted or unsubstituted heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 27 is independentlyoxo
- R 27 is piperidine. In embodiments, R 27 is piperazine.In embodiments, R 27 is pyridine.In embodiments, R 27 is pyrazine.In embodiments, R 27 is dimethylamino.In embodiments, R 27 is dimethylaminoethyl.In embodiments, R 27 is dimethylaminopropyl.In embodiments, R 27 is ethylmorpholinyl.In embodiments, R 27 is morpholinyl. [0183] R 28 is independentlyoxo,
- R 28 is piperidine. In embodiments, R 28 is piperazine.In embodiments, R 28 is pyridine.In embodiments, R 28 is pyrazine.In embodiments, R 28 is dimethylamino.In embodiments, R 28 is dimethylaminoethyl.In embodiments, R 28 is dimethylaminopropyl.In embodiments, R 28 is ethylmorpholinyl.In embodiments, R 28 is morpholinyl.
- R 2 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 31 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 32 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 32 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 32 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 32 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 3 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 34 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 34 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 34 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 35 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 35 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 35 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 35 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- R 4 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 37 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 37 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 37 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 38 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 38 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 38 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 38 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 5 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 40 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 40 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 40 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 41 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 41 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 41 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 41 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- R 9 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 43 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 43 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 43 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 44 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 44 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 44 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 44 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 10 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 46 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 46 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 46 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 47 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 47 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 47 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 47 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- R 11 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 49 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 49 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 49 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 50 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 50 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 50 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 50 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 12 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 52 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 52 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 52 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 53 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 53 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 53 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 53 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 13 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 55 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 55 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 55 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 56 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 56 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 56 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 56 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- aryl e.g.C 6 -C 10 aryl or C 6 aryl
- heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 14 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 58 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 58 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 58 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 59 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 59 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 59 -substituted or unsubstituted aryl e.g.C 6 -C 10 aryl or C 6 aryl
- R 59 - substituted or unsubstituted heteroaryl e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl.
- R 15 is independentlyhydrogen, oxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 61 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 61 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 61 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 62 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 62 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 62 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 62 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- R 16 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 64 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 64 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 64 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 65 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 65 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- heterocycloalkyl R 65 -substituted or unsubstituted aryl (e.g.C 6 -C 10 aryl or C 6 aryl), or R 65 - substituted or unsubstituted heteroaryl (e.g.5 to 10 membered heteroaryl, 5 to 9 membered heteroaryl, or 5 to 6 membered heteroaryl).
- R 17 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 67 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 67 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 67 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 68 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 68 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
- R 68 -substituted or unsubstituted aryl e.g.C 6 -C 10 aryl or C 6 aryl
- R 68 - substituted or unsubstituted heteroaryl e.g.5 to
- R 18 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 70 -substituted or unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 70 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 70 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered
- R 70 is independentlyoxo,
- unsubstituted heteroalkyl e.g.2 to 8 membered heteroalkyl, 2 to 6 membered heteroalkyl, or 2 to 4 membered heteroalkyl
- R 71 -substituted or unsubstituted cycloalkyl e.g.C 3 -C 8 cycloalkyl, C 4 - C 8 cycloalkyl, or C 5 -C 6 cycloalkyl
- R 71 -substituted or unsubstituted heterocycloalkyl e.g.3 to 8 membered heterocycloalkyl, 4 to 8 membered heterocycloalkyl, or 5 to 6 membered heterocycloalkyl
- R 71 -substituted or unsubstituted aryl e.g.C 6 -C 10 aryl or C 6 aryl
- R 71 - substituted or unsubstituted heteroaryl e.g.5 to
- R 19 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 20 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 21 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 22 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 23 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 24 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 25 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- R 26 is independentlyhydrogen, oxo, halogen, -CF 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, -SO 4 H, -SO 2 NH 2 , -NHNH 2 , -ONH 2 ,
- Lis independentlya bond, R 80 -substituted or unsubstituted alkylene, R 80 -substituted or unsubstituted heteroalkylene, R 80 -substituted or unsubstituted cycloalkylene, R 80 -substituted or unsubstituted heterocycloalkylene, R 80 -substituted or unsubstituted arylene, or R 80 -substituted or unsubstituted heteroarylene.
- R 29 , R 32 , R 35 , R 38 , R 41 , R 44 , R 47 , R 50 , R 53 , R 56 , R 59 , R 62 , R 65 , R 68 , R 71 , R 72 , R 73 , R 74 , R 75 , R 76 , R 77 , R 78 , R 79 , and R 80 are independentlyoxo,
- the compound is a compound described herein.In some embodiments, the compound is a compound described herein.In some embodiments, the compound is a compound described herein.In some
- the compound is not a compound selected from JD101 to JD160 (e.g., JD101, JD102, JD103, JD104, JD105, JD106, JD107, JD108, JD109, JD110, JD111, JD112, JD113, JD114, JD115, JD116, JD117, JD118, JD119, JD120, JD121, JD122, JD123, JD124, JD125, JD126, JD127, JD128, JD129, JD130, JD131, JD132, JD133, JD134, JD135, JD136, JD137, JD138, JD139, JD140, JD141, JD142, JD143, JD144, JD145, JD146, JD147, JD148, JD149, JD150, JD151, JD152, JD153, JD154, JD155, JD156, JD157, JD
- a compound as described herein mayinclude multiple instances ofR 1 , R 2 , R 3 , R 4 , R 5 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , m1, m2, m3, m4, m5, v1, v2, v3, v4, v5, n1, n2, n3, n4, n5, X, X a , X b , X c , X d and X e , and/or other variables.
- eachvariable mayoptional be different and be appropriately labeled to distinguisheachgroup for greater clarity.For example, where eachR 1 , R 2 , R 3 , R 4 , R 5 , R 9
- the compound competes withestrogen for binding to estrogen receptor (ER).
- the compound competes with4-hydroxytamoxifen for binding to ER.
- the compound binds the ligand binding domain ofER.
- the compound modulates the conformation ofhelix12 ofER relative to the conformation ofhelix12 when estrogen is bound to ER.
- the compound modulates (e.g., reduces relative to estrogen bound ER)the binding ofER to estrogen response elements.
- the compound modulates (e.g., reduces relative to estrogen bound ER)the phosphorylation ofER.
- the compound modulates (e.g., reduces relative to estrogen bound ER)the activity ofa cellular pathway(e.g., ras-MAPK containing pathway, PI3K/AKTcontaining pathway, Shc containing pathway, Src kinase containing pathway, JAK/STATcontaining pathway, nitric oxide synthase pathway
- the composition includes a CDK4 inhibitor.In embodiments, the composition does not include a CDK6 inhibitor.In embodiments, the composition includes a CDK6 inhibitor.In embodiments, the composition does not include a CDK4 inhibitor. [0241] In accordance withthe aspects ofthe present disclosure, it was unexpectedlyand surprisinglyfound that the compounds described herein synergizes withan amount ofa CDK4 inhibitor or a CDK6 inhibitor to elicit enhanced inhibition ofcell proliferation ofcancer cells, suchas NSCLC cells, as compared to when used individuallyand separately(i.e., monotherapy treatment). [0242] In embodiments, the compound and the CDK4 inhibitor are present in the composition in a synergistic amount.
- the compound and the CDK6 inhibibor are present in the composition in a synergistic amount.
- a synergistic amount maybe about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,
- a synergistic amount maybe about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.
- the synergistic effect maybe a compound activitydecreasing effect and/or a CDK4 inhibitor or CDK6 inhibitor decreasing effect.
- synergybetween the compound and the CDK4 inhibitor or the CDK6 inhibitor mayresult in about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4
- compositions including a pharmaceuticallyacceptable excipient, a further agent or additional agent as defined herein, such as a CDK4 inhibitor or a CDK6 inhibitor, and a compound, or pharmaceuticallyacceptable salt thereof, as described herein, including embodiments (e.g.compound offormula I, Ia, Ib, II, IIa, IIb, or anyembodiment thereof, or in an example, table, figure, or claim).
- the compound is a compound selected from JD101 to JD160, as disclosed herein.
- the CDK4 inhibitor or CDK6 inhibitor, and the compound, or pharmaceuticallyacceptable salt thereof, as described herein are eachincluded in a
- the pharmaceutical composition includes an additional agent or further agent (e.g.therapeutic agent).
- the pharmaceutical composition includes a further agent (e.g. therapeutic agent)in a therapeuticallyeffective amount.
- the further agent is an agent for treating cancer (an anti-cancer agent).
- the further agent is an agent for treating a hyperproliferative disorder.
- the further agent is an anti-cancer agent.
- the further agent is a chemotherapeutic.
- the further agent is an agent for treating breast cancer.
- the further agent is an agent for treating lung cancer.
- the further agent is an agent for treating a gynecological cancer.
- the further agent is an agent for treating ovarian cancer.
- the further agent is an agent for treating endometrial cancer.
- the further agent is an agent for treating prostate cancer
- the further agent is an aromatase inhibitor.
- the further agent is a HER-2 inhibitor.
- the further agent is Herceptin.
- the further agent is fulvestrant, clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene, ospemifene, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, aminoglutethimide, or testolactone.
- the further agent is tamoxifen.
- the further agent is an EGFR inhibitor (e.g.gefitinib (IressaTM), erlotinib (Tarceva TM), cetuximab (ErbituxTM), lapatinib (TYKERBTM), panitumumab (VECTIBIXTM), vandet
- EGFR inhibitor e.g.gefit
- the further agent is a mammalian target ofrapamycin (mTOR) inhibitor (suchas everolimus)for use in treating cancer (e.g.in breast and NSCLC tumors); HER2-targeted therapeutics (suchas trastuzumab, lapatinib, trastuzumab- emtansine)for use in treating cancer (e.g.ER-positive breast cancers withoverexpression ofHER-2 receptors);HER3- targeted agents (e.g.pertuzumab);EGFR-targeted therapeutics (suchas erlotinib, gefitinib, afitinib)for treating cancer (e.g.NSCLC expressing mutant EGFR or having EGFR-positivity); tamoxifen or aromatase inhibitors
- mTOR mammalian target ofrapamycin
- HER2-targeted therapeutics suchas trastuzumab, lapatinib, trastuzumab- emtansine
- kits including a further agent or additional agent as defined herein, suchas a CDK4 inhibitor or a CDK6 inhibitor, and a compound as disclosed herein (e.g., a compound having the structure ofFormula I’, I, Ia, Ib, II, IIa, IIb), or
- kits including a CDK4 inhibitor or a CDK6 inhibitor;and a
- R 1 is independentlya hydrogen, halogen, -NR 2 R 3 , -CX a
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl.
- R 4 is independentlya hydrogen, halogen, -CX d
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independentlyhydrogen,
- the kit further includes instructions for pharmaceutical use.
- the compound and the CDK4 inhibitor are present in the kit in a synergistic amount.
- the compound and the CDK6 inhibibor are present in the kit in a synergistic amount.
- a method for treating a hyperproliferative disorder in a subject in need thereof including administering to the subject an effective amount ofa composition disclosed herein;or the compound and the further agent (e.g.the CDK4 inhibitor or CDK6 inhibitor)ofthe kit as disclosed herein.
- the method includes administering a compound provided herein suchas a comfpounfofFormula Iand embodiments thereof, and an additional agent or further agent, suchas a CDK4 inhibitor or CDK6 inhibitor.
- the hyperproliferative disorder is associated withestrogen receptor activity.
- the hyperproliferative disorder is lymphangioleiomyomatosis.
- the hyperproliferative disorder is a cancer.
- the hyperproliferative disorder is a cancer resistant to an anti-cancer agent (e.g., tamoxifen, an antiestrogen, an aromatase inhibitor).
- the cancer is breast cancer.
- the cancer is breast cancer, lung cancer, a gynecological cancer, ovarian cancer, endometrial cancer, or prostate cancer.
- the cancer is ER positive breast cancer.
- the cancer is ER negative breast cancer.
- the cancer is hormone sensitive breast cancer.
- the cancer is hormone insensitive breast cancer.
- the cancer is triple negative breast cancer.
- the cancer is HER-2 positive breast cancer.
- the cancer is metastatic breast cancer.In embodiments, the
- the hyperproliferative disorder is a cancer ofan estrogen target organ or tissue.
- the cancer is non-small cell lung cancer.
- the cancer is small cell lung cancer.
- the lung cancer is adenocarcinoma.
- the lung cancer is squamous-cell carcinoma.
- the lung cancer is large-cell carcinoma.
- the lung cancer is bronchioloalveolar carcinoma.
- the lung cancer is stage I.In embodiments, the lung cancer is stage II.In embodiments, the lung cancer is stage III.In embodiments, the lung cancer is stage IV.
- the method or use includes administering a further agent (e.g.therapeutic agent).
- a further agent e.g.therapeutic agent
- the method or use includes administering a further agent (e.g.therapeutic agent)in a therapeuticallyeffective amount.
- the further agent is an agent for treating cancer.
- the further agent is an agent for treating a therapeuticallyeffective amount.
- the further agent is an anti-cancer agent. In embodiments, the further agent is a chemotherapeutic.In embodiments, the further agent is an agent for treating breast cancer.In embodiments, the further agent is an agent for treating lung cancer.In embodiments, the further agent is an agent for treating a gynecological cancer.In embodiments, the further agent is an agent for treating ovarian cancer.In embodiments, the further agent is an agent for treating endometrial cancer.In embodiments, the further agent is an agent for treating prostate cancer. In embodiments, the further agent is an agent for treating lymphangioleiomyomatosis (LAM).In embodiments, the further agent is an agent for inhibiting estrogen receptor activity.In embodiments, the further agent is an agent for treating a disease associated withestrogen receptor activity.In embodiments, the further agent is an antiestrogen.
- the further agent is a chemotherapeutic.In embodiments, the further agent is an agent for treating breast cancer.In embodiments, the further agent is an agent for treating lung cancer.In
- the further agent is an aromatase inhibitor.
- the further agent is an endocrine therapeutic.
- the further agent is an anti-cancer agent.
- the further agent is a chemotherapeutic.
- the further agent is a HER-2 inhibitor.
- the further agent is fulvestrant, clomifene, femarelle, ormeloxifene, raloxifene, tamoxifen, toremifene, lasofoxifene, ospemifene, anastrozole, letrozole, exemestane, vorozole, formestane, fadrozole, aminoglutethimide, or testolactone.
- the further agent is tamoxifen.
- the method or use does not include an increased riskofendometrial cancer.
- the method or use does not include an increased riskofa gynecological cancer.
- the method includes administration of a further agent in combination withthe compounds provided herein suchas the compound ofFormula I(or pharmaceutically acceptable salt thereof).
- the further agent is an anti-cancer compound as disclosed herein.
- the further agent is Buparlisib (BKM120), Pietilisib
- the further agent is Buparlisib (BKM120), BAY80-6946, Taselisib (GDC0032), Alpelisib (BYL719), Idelalisib (CAL-101), or Duvelisib (IPI-145).
- the further agent is an inhibitor ofPI3K,
- the further agent is administered contemporaneouslywiththe composition or compound disclosed herein, or pharmaceuticallyacceptable salt thereof.
- the further agent is administered sequentially.
- the further agent e.g., tamoxifen, exemestane, letrozole, anastrazole or enzalutamide
- the further agent is adriamycin, a taxane, cyclophosphamide, fluorouracil, methotrexate, cisplatin, or carboplatin.
- the further agent is metformin or analog thereof, as known in the art.
- the further agent is an NF -B inhibitor (e.g., parthenolides or parthenolide derivatives).
- the further agent is an estrogen receptor-beta targeted agent.In embodiments, the further agent inhibits EGFR, HER2 and/or HER3.
- compositions as described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination with a further agent for use in the treatment ofgynecomastia in a subject in need of suchtreatment.
- the use includes administering to the subject a therapeuticallyeffective amount ofa composition described herein, or a compound as described herein or pharmaceutically acceptable salt thereofin combination with a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor).
- the use mayinclude administering to the subject a therapeuticallyeffective amount ofa compound described herein in combination witha therapeuticallyeffective amount ofa further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor).
- gynecomastia is associated withestrogen receptor activity.
- gynecomastia is non-physiologic gynecomastia.
- gynecomastia is physiologic gynecomastia.
- the method or use improves (e.g.increases)bone densityrelative to the absence ofthe compound.
- the method or use improves (e.g.increases)bone mass relative to the absence ofthe compound.
- the method or use improves (e.g.
- the method or use is a treatment for osteoporosis, osteogenesis imperfecta, or osteopenia. In embodiments, the method or use is a treatment for osteogenesis imperfecta. [0275] In embodiments, the method or use is used to prevent bone deterioration, prevent bone degradation, prevent bone degeneration, prevent loss ofbone mass, prevent loss ofbone density, stabilize bone deterioration, stabilize bone degradation, stabilize bone degeneration, stabilize the loss ofbone mass, stabilize the loss ofbone density, decrease bone deterioration, decrease bone degradation, decrease bone degeneration, decrease loss ofbone mass, decrease loss ofbone density, increase bone mass, increase bone density, or combinations thereof.
- a method oftreating a bone disorder in a subject in need thereof including administering to the subject an effective amount ofa composition described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination with a further agent (e.g.a CDK 4 inhibitor or CDK 6 inhibitor).
- a further agent e.g. a CDK 4 inhibitor or CDK 6 inhibitor.
- use of a composition as described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination witha CDK 4 inhibitor or CDK 6 inhibitor in the manufacture ofa medicament for the treatment ofa bone disorder in a subject in need ofsuchtreatment.
- a composition as described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination with a further agent for use in the treatment ofa bone disorder in a subject in need of suchtreatment.
- the use includes administering to the subject a composition described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination with a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor).
- the use mayinclude administering to the subject a therapeuticallyeffective amount ofa composition described herein, or a compound as described herein or pharmaceuticallyacceptable salt thereofin combination witha further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor).
- the bone disorder is osteoporosis, osteogenesis imperfecta, or osteopenia.
- the bone disorder is osteogenesis imperfecta.
- the bone disorder is bone deterioration, bone degradation, bone degeneration, loss ofbone mass, loss ofbone density, or combinations thereof.
- the method or use is used to prevent bone deterioration, prevent bone degradation, prevent bone degeneration, prevent loss ofbone mass, prevent loss ofbone density, stabilize bone deterioration, stabilize bone degradation, stabilize bone degeneration, stabilize the loss ofbone mass, stabilize the loss ofbone density, decrease bone deterioration, decrease bone degradation, decrease bone degeneration, decrease loss ofbone mass, decrease loss ofbone density, increase bone mass, increase bone density, or combinations thereof.
- the method or use includes administering a compound described herein in combination with a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)as disclosed herein.
- a further agent e.g.CDK 4 inhibitor or CDK 6 inhibitor
- use of a compound as described or pharmaceuticallyaccept salt thereofand a further agent e.g.CDK 4 inhibitor or CDK 6 inhibitor)as disclosed herein in the manufacture ofa medicament for the treatment ofa hyperproliferative disorder in a subject in need ofsuchtreatment.
- a compound as disclosed herein, or pharmaceuticallyaccept salt thereof, and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)as disclosed herein for use in the treatment ofa hyperproliferative disorder in a subject in need ofsuchtreatment includes administering to the subject a compound disclosed herein, or pharmaceutically accept salt thereof, and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor).
- the use may include administering to the subject a therapeuticallyeffective amount ofa composition described herein.
- the method for treating a hyperproliferative disorder includes the adiminstration ofa composition where the compound and the CDK4 inhibitor are present in the composition in a synergistic amount.
- the method for treating a hyperproliferative disorder includes the adiminstration of a composition where the compound and the CDK6 inhibitor are present in the composition in a synergistic amount.
- Methods of Inhibiting Estrogen Receptor [0286] In an aspect is provided a method ofinhibiting estrogen receptor activityin a subject in need thereof. The method includes administering to the subject an effective amount ofa composition as disclosed herein, or a compound or pharmaceuticallyacceptable salt thereofa further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)ofthe kit disclosed herein.Thus, in embodiments, the method includes administering a compound provided herein suchas a comfpounfofFormula Iand embodiments thereof, and an additional agent or further agent, such as a CDK4 inhibitor or CDK6 inhibitor.
- the method or use includes modulation (e.g., inhibition or reduction) ofthe activityofa cellular pathway(e.g., ras-MAPK containing pathway, PI3K/AKTcontaining pathway, Shc containing pathway, Src kinase containing pathway, JAK/STATcontaining pathway, nitric oxide synthase pathway, VEGFsecretion pathway).
- the method or use includes modulation (e.g., inhibition or reduction)ofDNA synthesis.
- the method or use includes modulation (e.g., inhibition or reduction)ofcell growth.
- the method or use includes modulation (e.g., inhibition or reduction)ofcell proliferation. In embodiments, the method or use includes modulation (e.g., inhibition or reduction)ofepithelial cell proliferation. In embodiments, the method or use includes modulation (e.g., activation or increasing)ofthe degradation ofER. In embodiments, the method or use includes modulation (e.g., activation or increasing)ofthe ubiquitination ofER. In embodiments, the method or use includes modulation (e.g., activation or increasing)ofthe degradation ofER bythe proteasome. In embodiments, the method or use includes modulation (e.g., inhibition or reduction) of ER interaction with AP-1, NF- ⁇ B, MAPK, PI3K, or AKT kinase.
- the method or use includes modulation (e.g., inhibition or reduction)ofER phosphorylation.
- the method or use includes modulation (e.g., activation or increasing)oftumor cell apoptosis.
- the method or use includes modulation (e.g., activation or increasing)ofcancer cell apoptosis.
- the method or use includes modulation (e.g., activation or increasing)ofER expressing cell apoptosis.
- the method or use includes modulation (e.g., inhibition or reduction)ofER translocation to the nucleus.
- the method or use includes modulation (e.g., inhibition or reduction)ofER translocation to the cytosol.
- the method or use includes administering a composition described herein, or a compound or pharmaceuticallyacceptable salt thereof disclosed herein and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)disclosed herein.
- a further agent e.g.CDK 4 inhibitor or CDK 6 inhibitor
- use of a composition as described herein, or a compound or pharmaceuticallyacceptable salt thereofdisclosed herein and a further agent e.g.CDK 4 inhibitor or CDK 6 inhibitor
- a composition as described herein, or a compound or pharmaceuticallyacceptable salt thereofdisclosed herein and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)disclosed herein, for use in inhibiting estrogen receptor activityin a subject in need ofsuchtreatment includes administering to the subject a composition, or a compound or pharmaceuticallyacceptable salt thereofdisclosed herein and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)disclosed herein described herein.
- the use may include administering to the subject a therapeuticallyeffective amount ofa composition described herein, or a compound or pharmaceuticallyacceptable salt thereofdisclosed herein and a further agent (e.g.CDK 4 inhibitor or CDK 6 inhibitor)disclosed herein described herein.
- the method ofinhibiting estrogen receptor activityin a subject includes the adiminstration of a composition where the compound and the CDK4 inhibitor are present in the composition in a synergistic amount.
- the method ofinhibiting estrogen receptor activityin a subject includes the adiminstration of a composition where the compound and the CDK6 inhibitor are present in the composition in a synergistic amount.
- Embodiment 1 A composition comprising: a CDK4 inhibitor or a CDK6 inhibitor;and
- R 1 is independentlya hydrogen, halogen, -NR 2 R 3 , -CX a
- heteroalkylene substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, substituted or unsubstituted
- heteroarylene or a substituted or unsubstituted spirocyclic linker
- R 2 is independentlya hydrogen, halogen, -CX b
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl;
- R 4 is independentlya hydrogen, halogen, -CX d
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independently hydrogen, halogen, -CX 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, - SO 4 H,
- n is an integer from 0 to 5;
- n 1 or 2;
- n1, n2, n3, and n4 are independentlyan integer from 0 to 4;
- X, X a , X b , X c and X d are independently–Cl, -Br, -I, or -F.
- Embodiment 2 The composition ofembodiment 1, the compound having the formula:
- R 5 is independentlya hydrogen, halogen, -CX e
- R 23 , R 24 , R 25 , and R 26 are independentlyhydrogen
- n5 is independentlyan integer from 0 to 4.
- Embodiment 3 The composition ofembodiment 2, wherein R 5 ofthe compound is independentlya hydrogen, halogen, -CX e
- Embodiment 4 The composition ofembodiment 2, wherein R 5 ofthe compound is independentlya hydrogen, -F, -CF 3 , or unsubstituted methyl.
- Embodiment 5 The composition ofembodiment 1, the compound having the formula:
- Embodiment 6 The composition ofembodiment 1, the compound having the formula:
- Embodiment 7 The composition ofembodiment 1, the compound having the formula:
- R 5 is independentlya hydrogen, halogen, -CX e
- R 23 , R 24 , R 25 , and R 26 are independentlyhydrogen
- n5 is independentlyan integer from 0 to 4.
- Embodiment 8 The composition ofembodiment 7, wherein R 5 ofthe compound is independentlya hydrogen, halogen, -CX e
- Embodiment 9 The composition ofembodiment 7, wherein R 5 ofthe compound is independentlya hydrogen, -F, -CF 3 , or unsubstituted methyl.
- Embodiment 10 The composition ofembodiment 1, the compound having the formula: IIb).
- Embodiment 11 The composition ofembodiment 1, wherein Lofthe compound is a bond.
- Embodiment 12 The composition ofembodiment 1, wherein Lofthe compound is a heteroalkylene.
- Embodiment 13 The composition ofembodiment 1, wherein Lofthe compound is independentlya 2 to 8 membered heteroalkylene.
- Embodiment 14 The composition ofembodiment 1, wherein Lofthe compound is independentlya 3 to 6 membered heteroalkylene.
- Embodiment 15 The composition ofembodiment 1, wherein Lofthe compound is independently–NH-(substituted or unsubstituted (C 1 -C 4 )alkylene).
- Embodiment 16 The composition ofembodiment 1, wherein Lofthe compound is independently–NH-(unsubstituted (C 1 -C 4 )alkylene).
- composition ofembodiment 1 wherein Lofthe compound is independently–NHC(O)-(substituted or unsubstituted (C 1 -C 4 )alkylene).
- Embodiment 18 The composition ofembodiment 1, wherein Lofthe compound is independently
- Embodiment 19 The composition ofembodiment 1, wherein R 2 ofthe compound is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.
- Embodiment 20 The composition ofembodiment 1, wherein R 2 ofthe compound is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substituted or unsubstituted 2 to 10 membered heteroalkyl.
- Embodiment 21 The composition ofembodiment 1, wherein R 2 ofthe compound is unsubstituted methyl.
- Embodiment 22 The composition ofembodiment 1, wherein R 2 ofthe compound is H.
- Embodiment 23 The composition ofembodiment 1, wherein R 3 ofthe compound is independentlysubstituted or unsubstituted alkyl or substituted or unsubstituted heteroalkyl.
- Embodiment 24 Embodiment 24.
- composition ofembodiment 1, wherein R 3 ofthe compound is independentlysubstituted or unsubstituted (C 1 -C 10 )alkyl or substituted or unsubstituted 2 to 10 membered heteroalkyl.
- Embodiment 25 The composition ofembodiment 1, wherein R 3 ofthe compound is unsubstituted methyl.
- Embodiment 26 The composition ofembodiment 1, wherein R 3 ofthe compound is H.
- Embodiment 27 The composition ofembodiment 1, wherein R 2 and R 3 ofthe compound are joined to form a substituted or unsubstituted heterocycloalkyl.
- Embodiment 28 Embodiment 28.
- Embodiment 29 The composition ofembodiment 1, wherein R 2 and R 3 ofthe compound are joined to form a substituted or unsubstituted 3 to 8 membered heterocycloalkyl.
- Embodiment 30 The composition ofembodiment 1, wherein R 2 and R 3 ofthe compound are joined to form an unsubstituted 3 to 6 membered heterocycloalkyl.
- Embodiment 31 The composition ofembodiment 1, wherein R 2 and R 3 ofthe
- Embodiment 32 The composition ofembodiment 1, wherein n ofthe compound is 2.
- Embodiment 33 The composition ofembodiment 1, wherein n ofthe compound is 1.
- Embodiment 34 The composition ofembodiment 1, wherein R 1 ofthe compound is –NO 2 or–NH 2 .
- Embodiment 35 The composition ofembodiment 34, wherein Lofthe compound is a bond.
- Embodiment 36 The composition ofembodiment 1, the compound having the formula:
- Embodiment 37 The composition ofembodiment 1 comprising a CDK4 inhibitor.
- Embodiment 38 The composition ofembodiment 37 not comprising a CDK6 inhibitor.
- Embodiment 39 The composition ofembodiment 1 comprising a CDK6 inhibitor.
- Embodiment 40 The composition ofembodiment 39 not comprising a CDK4 inhibitor.
- Embodiment 41 The composition ofone ofembodiments 1 to 40, further comprising a pharmaceuticallyacceptable excipient therebyforming a pharmaceutical composition.
- Embodiment 42 Embodiment 42.
- composition ofembodiment 41 wherein the compound is in a first dosage form and the CDK4 inhibitor or the CDK6 inhibitor is in a second dosage form.
- Embodiment 43 The composition ofembodiment 41, wherein the pharmaceutical composition is a single dosage form.
- Embodiment 44 A kit comprising a CDK4 inhibitor or a CDK6 inhibitor;and
- heteroalkylene substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, substituted or unsubstituted
- heteroarylene or a substituted or unsubstituted spirocyclic linker
- R 2 is independentlya hydrogen, halogen, -CX b
- R 3 is independentlya hydrogen, halogen, -CX c
- R 2 and R 3 substituents mayoptionallybe joined to form a substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl;
- R 4 is independentlya hydrogen, halogen, -CX d
- R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 are independently hydrogen, halogen, -CX 3 , -CN, -OH, -NH 2 , -COOH, -CONH 2 , -NO 2 , -SH, -SO 2 Cl, -SO 3 H, - SO 4 H,
- n is an integer from 0 to 5;
- n 1 or 2;
- n1, n2, n3, and n4 are independentlyan integer from 0 to 4;
- X, X a , X b , X c and X d are independently–Cl, -Br, -I, or -F.
- Embodiment 45 The kit ofembodiment 44, wherein the compound is in a first dosage form further comprising a pharmaceuticallyacceptable excipient and the CDK4 inhibitor or the CDK6 inhibitor is in a second dosage form further comprising a pharmaceutically acceptable excipient.
- Embodiment 46 The kit ofembodiment 44, wherein the compound and the CDK4 inhibitor or the CDK6 inhibitor are within a dosage form further comprising a pharmaceutically acceptable excipient.
- Embodiment 47 Embodiment 47.
- Embodiment 48 A method oftreating a hyperproliferative disorder in a subject in need thereof, comprising administering to the subject an effective amount of a composition of anyone ofembodiments 1 to 43 or the compound and the CDK4 inhibitor or CDK6 inhibitor of the kit ofone ofembodiments 44 to 50.
- Embodiment 49 The method ofembodiment 48, wherein the hyperproliferative disorder is associated withestrogen receptor activity.
- Embodiment 50 The method ofembodiment 48, wherein the hyperproliferative disorder is lymphangioleiomyomatosis.
- Embodiment 51 The method ofembodiment 48, wherein the hyperproliferative disorder is a cancer.
- Embodiment 52 The method ofembodiment 51, wherein the cancer is resistant to an anti-cancer agent.
- Embodiment 53 The method ofembodiment 51, wherein the cancer is breast cancer, lung cancer, a gynecological cancer, ovarian cancer, endometrial cancer, or prostate cancer.
- Embodiment 54 The method ofembodiment 51, wherein the cancer is a cancer of an estrogen target organ or tissue.
- Embodiment 55 Embodiment 55.
- a method ofinhibiting estrogen receptor activityin a subject in need thereof, comprising administering to the subject an effective amount of a composition of anyone ofembodiments 1 to 43 or the CDK4 inhibitor or CDK6 inhibitor ofthe kit ofone of embodiments 44 to 50.
- Embodiment 56 The composition ofanyone ofembodiments 1-43, wherein the compound and the CDK4 inhibitor or the CDK6 inhibibor are present in the composition in a synergistic amount.
- Embodiment 57 The kit ofanyone ofembodiments 44-47, wherein the compound and the CDK4 inhibitor or said CDK6 inhibibor are present in the kit in a synergistic amount.
- Embodiment 58 The methods ofanyone ofembodiments 48-55, wherein the compound and the CDK4 inhibitor or the CDK6 inhibibor are present in the composition in a synergistic amount.
- the phenolic hydroxyl group ofOHT binds to the same part ofthe ligand binding domain (LBD)as does the phenolic hydroxyl group ofE2 but, because ofthe hindered basic amino group in OHT(not present in E2), the waythe protein folds around the bound molecule is altered (helix12 folds in an unusual way)and the signal for DNA synthesis and cancer growthis inhibited.
- LBD ligand binding domain
- THF Tetrahydrofuran
- DMF dimethylformamide
- (8S,9S,13S,14S,17S)-3,17-bis(Benzyloxy)-13-methyl- 6,7,8,9,12,13,14,15,16,17-decahydro-11H-cyclopenta[a]phenanthren-11-one (11-ketone) was prepared using literature procedures.
- the coupling constants are reported in Hertz (Hz) and the resonance patterns are reported withnotations as the following: br (broad), s (singlet), d (double), t (triplet), q (quartet)and m (multiplet).
- High-resolution mass spectra were measured on a time-of-flight LC- MS.Thin-layer chromatography(TLC)was carried out using precoated silica gel sheets.Visual detection was performed withultraviolet light, p-anisaldehyde stain, potassium permanganate stain or iodine. Flash chromatography was performed using silica gel P60 (60 A, 40-63 ⁇ m) with compressed air.
- Example 2.Compound Functional Characterization For the biological testing alternative code names for the compounds were used, namely JD101-JD160. The correspondence ofthe compound numbers in the design and synthesis and the code names for functional characterization are given in Table 1. Table 1: Correspondence of the Novel ER Antagonists Chemical names and their alternative Code Names for Functional Characterization.
- Novel antiestrogen compounds can act as ER ⁇ downregulators.Fulvestrant (Faslodex R ) has been characterized as a selective ER ⁇ downregulator and a pure anti-estrogen. Fulvestrant inhibits the transcriptional response to estrogen stimulation and induces the degradation of estrogen receptor proteins (46,47). This drug has been demonstrated to be clinicallyeffective in treating metastatic breast cancer and represents an important option to extend the window of endocrine interventions before cytotoxic chemotherapybecomes the onlyother systemic treatment available for patients.
- One problem withfulvestrant is that the drug requires intramuscular injection and maynot achieve optimal antitumor effects due to the limited doses that can be administered bythis drug deliverymethod.
- MCF-7 breast cancer cells with high expression of ER ⁇ protein were treated with estradiol-17 ⁇ and either 1 ⁇ M or 10 ⁇ M concentrations of JD128 and JD140 for 48 hours.
- FIG.3 shows results of W estern immunoblots of ER ⁇ protein levels after treatments.
- Compound JD128 showed the greatest effect at suppressing estrogen receptor-alpha expression in MCF-7 breast cancer cells.As shown in FIG.3, estrogen receptor-alpha is down-regulated by antiestrogens.
- MCF-7 breast cancer cells were estrogen-deprived for 48 hrs, then treated with1 nM estradiol-17 ⁇ (E2) or antiestrogens JD128 (128) or JD140 (140) at 1 ⁇ M or 10 ⁇ M
- TAM-R cells To develop TAM-R cells, MCF-7 breast cells were cultivated invitro in the presence oftamoxifen as reported before (72).In brief, MCF-7 cell monolayers were cultivated in phenol-red-free RPMImedium containing 5% charcoal-stripped steroid-depleted (DCC)-fetal calfserum, antibiotics, glutamine (200 mM), and 4- hydroxytamoxifen (1 x10-7 M 4-OH-TAM).Cells were continuouslyexposed to this treatment for 12 months, during whichtime medium was replaced every4 days, and cell cultures were passaged bytrypsinization after 70% confluencywas reached. Initially, MCF-7 cell growthrates were reduced but, after 4 months’exposure to the medium, cell growthgraduallyincreased, indicating development ofa cell line resistant to the growth-inhibitoryproperties of4-OH-TAM.
- DCC charcoal-stripped steroid-depleted
- glutamine 200 mM
- TAM-resistant This cell line, termed TAM-resistant, was cultured for a further 8 months in medium containing 4-OH-TAM before characterization studies. These cells were evaluated for expression ofEGFR, HER-2 and ER ⁇ -(FIG.2). The results show that TAM-resistant cells have higher levels ofHER-2 and EGFR as compared withtamoxifen-sensitive progenitor MCF-7 cells, while expression levels ofER remain essentiallyunchanged.This finding mayhave important implications for the design offuture therapeutic interventions.
- FIG.4a-b. shows MCF-7 cells withacquired tamoxifen resistance show increased expression ofHER-1/EGFR and HER-2 receptors.
- FIG.4a shows a W estern blot showing protein expression level ofHER2, EGFR, ER - and actin loading control in MCF-7 cells that were tamoxifen-sensitive (left)versus those that were tamoxifen- resistant (right).
- FIG.4b shows levels ofHER-2, HER-1/EGFR and ER - receptors in MCF-7/TAM-R cells that were quantitated using established ELISA methods (73), withresults based on 3
- MCF-7/TAM-R, MCF-7/ER- and parental cells MCF-7/CON (parental) cells are tamoxifen-sensitive, while MCF-7/TAM-R and MCF-7/ER- cells are known to be tamoxifen-resistant (11,14-16).
- TAM-R (72)and MCF-7/ER- (16) cells are routinely cultured in RPMI1640 media with10% heat-inactivated FBS.For E2-free conditions, medium is changed 48 hbefore studies to phenol-red free RPMI1640 with1% dextran-coated, charcoal- treated (DCC) FBS.
- MCF-7/CON cells express ER ⁇ but few HER2 receptors
- MCF-7/TAM-R cells express bothER and HER2.
- ER and HER2 were detected by established immunofluorescence microscopy methods with labeled antibodies to ER ⁇ and HER2 (14-16).
- TAM-R cells also show increased expression ofHER2 byimmunofluorescence (72).
- expression of ER ⁇ appears to be relatively stable among the several cell lines, withonlymodestlyless intensityofimmunofluorescence in TAM-R cells as compared to their paired controls.
- [ 3 H]estradiol-17 - and varying concentrations (1 nM-10 ⁇ M)ofnew estrogen receptor downregulator (ERD)analogues The efficiencyofthe binding ofcompounds was measured by the loss ofradioactivityofthe [ 3 H]estradiol-17 -.A 100-fold molar excess ofunlabeled E2 was present with[3H]estradiol-17 - in paired samples for determination ofdisplaceable binding.ICI 182,780 (fulvestrant, 1 nM -10 -M)was used as a control.As shown in FIG.5, the ligand binding specificityoflabeled estradiol-17 - was suppressed effectivelyby10 ⁇ M ofERD compound S15 (JD105)compared to select test compounds.
- FIG.5 shows specific binding of [ 3 H]estradiol-17 - byMCF-7 parental breast cancer cells is suppressed byour ERD compound S15 in this series ofanalogues (15).MCF-7 cells were incubated with2
- Compounds S1-S14 show less activityin the assayabove than compound S15 (JD105)as shown in FIG.5.
- Compounds S1-S14 are test compounds different from the exemplified compounds described herein.
- ER down-regulation To determine ifselected compounds can down-regulate ER protein, we treated cells for 24-48 hrs in vitro withcandidate compounds at varying doses.Then, cells were disrupted and prepared for PAGE and W estern immunoblots using anti-ER ⁇ antibodies (see FIG.6).A representative experiment shows that a selected ERD at doses of>100 nM elicits reduced ER levels.Those ERDs withoptimal activityin down-regulating ER were investigated further in the chemistrylaboratoryto further refine and develop suchagents.
- FIG.6 shows ERD S15 reduces ER protein levels in MCF-7 breast tumor cells.W estern immunoblot analysis ofER (66 kD)after treatment ofMCF-7 cells for 24 hours withSERM S15 at various concentrations (10, 100 and 1000 nM), ICI182,780 (ICI;fulvestrant;100 nM), tamoxifen (TM;100 nM)or control vehicle (CON).
- ERD S15 inhibits phosphorylation ofMAPK, at both extracellular signal-regulated kinases ERK-1 (p44)and ERK-2 (p42).
- ERD S15 was as effective as fulvestrant in inhibiting the rapid estrogen-induced MAPK phosphorylation in breast tumor cells invitro.
- FIG.7 shows treatment ofMCF-7 parent cells with1 nM estradiol 17 - (E2) induces rapid phosphorylation ofMAPK (pMAPK).E2 but not vehicle (CN)induced rapid phosphorylation ofERK-1 (p44)and ERK-2 (p42).This activation was prevented when cells were pre-incubated with1000 nM ICI182,780 (ICI;Faslodex)or 1000 nM compound S15 in the presence ofestradiol (E2).
- human non-small cell lung cancer cells A549 were grown in RPMI1640 medium with10% fetal bovine serum (FBS), then treated witheither 1 -M or 10 -M doses ofestrogen receptor antagonists JD128, JD140 or fulvestrant.Cell counts and viabilitytests (Trypan blue)were done every24 hours for 3 days.After 72 hours, proliferation was assessed using the CELLTITER 96 TM AQ ueous One Solution Cell Proliferation Assay(MTS)from Promega.Cell numbers were also assessed initiallybycell counts to confirm ELISA data.Eachantiestrogen was tested in at least in three independent experiments.
- ER has a major role in controlling breast cancer growth.
- Antiestrogen tamoxifen has been the most widelyused hormone therapy, achieving a 39% reduction in breast cancer recurrence and 31% reduction in mortalityin ER-positive earlybreast cancer.
- Tamoxifen has important drawbacks: a limited period ofactivitybefore resistance develops;and undesirable side-effects in normal tissues suchas uterus due to the activityas a partial agonist.As long as ER is present, growthmaybe stimulated byestrogen, partial agonists or estrogen-independent action.Introduction ofaromatase inhibitors for postmenopausal patients, either initiallyor after tamoxifen, has yielded better outcomes than tamoxifen.However, in patients withadvanced breast cancer, onlyabout one third ofER-positive breast cancers respond to aromatase inhibitors, and resistance can evolve due to ER activation byER hypersensitivityor ligand-independent ER activ
- fulvestrant is a pure ER antagonist withno major agonist activityand witha unique mechanism ofaction, i.e.downregulation ofER, due in part to induced destabilization and hyper-ubiquitination ofER leading to growthinhibition.But, fulvestrant suffers from low bioavailabilitywhichpresents a problem in the clinic.In about 14% of metastatic ER-positive breast cancers from patients withmultiple prior endocrine therapies, there is emerging evidence for the acquisition offunctionally-aberrant ESR1 withpoint mutations.
- the human estrogen receptor-alpha is an ubiquitinated protein whose stabilityis affected differentiallyby agonists, antagonists, and selective estrogen receptor modulators.J.Biol.Chem.276, 35684– 356892.21.Robinson DR, W u YM, Vats P et al.(2013).Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Nat Genet 2013, 45:1446-1451.
- Example 5 Selective estrogen receptor downregulators and applications in ER- positive human cancers.
- SERD compounds e.g., compounds disclosed herein, show that several of these agents are effective in blocking proliferation ofhuman NSCLC cells invitro (see FIG.S1 and Table S1 following).
- DCC-FBS.Cell proliferation was measured using the MTS assay(Promega) as described in methods.Numbers represent the average of at least 3 experiments. NSCLC cells include A549, H1975 and H2122. The extra column on the right (MCF-7)is included to compare findings withthose on treatment of MCF-7 breast cancer cells; IC 50 ( ⁇ M) concentrations for inhibition ofcell proliferation after treatment withSERDs for 72 hrs in the presence of 1nM estradiol-17 ⁇ . MCF-7 cell proliferation was measured by
- CDK 4/6 phosphorylates/ inactivates retinoblastoma (Rb)protein, whichallows the E2F-DP complexto encode proteins integral to DNA replication, therebycommitting the cell to cell cycle progression.
- palbociclib PD0332991
- CDK4/6 inhibitor a selective cyclin D kinase (CDK)4/6 inhibitor, is reported to preferentiallyinhibit proliferation ofluminal ER --positive breast cancer cell lines in vitro (19,20).As shown in FIG.S3, it is notable that CDK 4/6 partners withcyclin D
- CDK 4/6 inhibitor palbociclib is currently FDA-approved for management ofadvanced ER --positive breast cancer in combination with letrozole or fulvestrant (19-22). Additional CDK 4/6 inhibitors are also being developed for management ofbreast and potentiallyother malignancies.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662342126P | 2016-05-26 | 2016-05-26 | |
PCT/US2017/034452 WO2017205611A1 (fr) | 2016-05-26 | 2017-05-25 | Associations de modulateurs du récepteur des oestrogènes |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3463342A1 true EP3463342A1 (fr) | 2019-04-10 |
EP3463342A4 EP3463342A4 (fr) | 2020-01-15 |
EP3463342B1 EP3463342B1 (fr) | 2023-09-06 |
Family
ID=60411906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17803574.7A Active EP3463342B1 (fr) | 2016-05-26 | 2017-05-25 | Associations de modulateurs du récepteur des oestrogènes |
Country Status (5)
Country | Link |
---|---|
US (1) | US10918648B2 (fr) |
EP (1) | EP3463342B1 (fr) |
JP (1) | JP6853833B2 (fr) |
CA (1) | CA3063834A1 (fr) |
WO (1) | WO2017205611A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220133747A1 (en) * | 2018-06-06 | 2022-05-05 | The Regents Of The University Of California | Estrogen receptor inhibitors and uses therof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5679788A (en) | 1993-06-17 | 1997-10-21 | Roussel Uclaf | 11 beta-substituted-19 nor-steroids |
ATE222922T1 (de) | 1998-11-20 | 2002-09-15 | Akzo Nobel Nv | Estrogenische estra-1,3,5(10)-trien verbindungen mit verschiedenen wirkungen auf estrogenrezeptor alpha und beta mit einer unverzweigten kohlenwasserstoffkette von 5-9 kohlenstoffatomen in position 11 |
US9315539B2 (en) | 2002-10-01 | 2016-04-19 | Yale University | 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer |
CN105294683B (zh) | 2014-07-26 | 2018-01-23 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
US10400006B2 (en) * | 2014-11-26 | 2019-09-03 | The Regents Of The University Of California | Estrogen receptor modulators |
-
2017
- 2017-05-25 WO PCT/US2017/034452 patent/WO2017205611A1/fr unknown
- 2017-05-25 US US16/302,060 patent/US10918648B2/en active Active
- 2017-05-25 CA CA3063834A patent/CA3063834A1/fr active Pending
- 2017-05-25 JP JP2018561709A patent/JP6853833B2/ja active Active
- 2017-05-25 EP EP17803574.7A patent/EP3463342B1/fr active Active
Also Published As
Publication number | Publication date |
---|---|
EP3463342B1 (fr) | 2023-09-06 |
WO2017205611A1 (fr) | 2017-11-30 |
US10918648B2 (en) | 2021-02-16 |
CA3063834A1 (fr) | 2017-11-30 |
EP3463342A4 (fr) | 2020-01-15 |
JP2019519532A (ja) | 2019-07-11 |
JP6853833B2 (ja) | 2021-03-31 |
US20190175614A1 (en) | 2019-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3630745A2 (fr) | Inhibiteurs covalents de kras | |
EP3350181B1 (fr) | Ligands her3 et utilisations de ceux-ci | |
AU2020270487B2 (en) | PCNA inhibitors | |
EP3445768A1 (fr) | Inhibiteurs de erbb et leurs utilisations | |
US10428048B2 (en) | Androgen receptor antagonists | |
EP3224230B1 (fr) | Modulateurs du récepteur des strogènes | |
EP3463342B1 (fr) | Associations de modulateurs du récepteur des oestrogènes | |
AU2016341884B2 (en) | Piperazinyl norbenzomorphan compounds and methods for using the same | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
WO2015196144A2 (fr) | Antagonistes du récepteur des androgènes | |
US11117894B2 (en) | Pyridopyrazine compounds and uses thereof | |
WO2023141635A2 (fr) | Ligands de her3 et leurs utilisations | |
WO2019236901A1 (fr) | Inhibiteurs de récepteurs des oestrogènes et utilisations correspondantes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20181220 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20191216 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/517 20060101ALI20191210BHEP Ipc: A61P 35/00 20060101ALI20191210BHEP Ipc: A61K 31/416 20060101AFI20191210BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20221020BHEP Ipc: A61K 31/565 20060101ALI20221020BHEP Ipc: A61K 31/519 20060101ALI20221020BHEP Ipc: A61K 31/506 20060101ALI20221020BHEP Ipc: A61K 31/517 20060101ALI20221020BHEP Ipc: A61P 35/00 20060101ALI20221020BHEP Ipc: A61K 31/416 20060101AFI20221020BHEP |
|
INTG | Intention to grant announced |
Effective date: 20221108 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20230405 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602017073849 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231206 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231207 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1607590 Country of ref document: AT Kind code of ref document: T Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240106 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230906 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240108 |